Melatonina
Pubblicato il 11/01/2015
Utilizzo:
In compresse da 2 mg in dosaggi di 20 mg o più al giorno. Da ingerire preferibilmente prima del pasto, distribuita uniformemente nel corso della giornata con concentrazione nettamente superiore la sera. Esempio: 2 compresse al mattino, 2 a mezzodì e 6 la sera prima di coricarsi.
In compresse da 2 mg in dosaggi di 20 mg o più al giorno. Da ingerire preferibilmente prima del pasto, distribuita uniformemente nel corso della giornata con concentrazione nettamente superiore la sera. Esempio: 2 compresse al mattino, 2 a mezzodì e 6 la sera prima di coricarsi.
Proprietà farmacologiche:
E’ un neurotrasmettitore prodotto principalmente dal sistema nervoso, ma anche dall’epifisi o ghiandola pineale e da vari distretti come le ghiandole di Harder, le piastrine, i megacariociti ecc. Viene prevalentemente prodotta di notte. Svolge fondamentali e documentati effetti nella prevenzione e terapia delle patologie tumorali e degenerative, oggetto di un numero crescente di studi e di ricerche. Si può considerare e distinguere un’azione antitumorale indiretta della melatonina attraverso l’inibizione dei radicali liberi e l’effetto antiossidante, unitamente alla protezione dall’effetto cancerogeno e degenerativo di campi elettrici e magnetici. Va considerato tra le azioni antitumorali indirette anche l’effetto antinvecchiamento e antidegenerativo del tessuto nervoso e vascolare, la proprietà antiaggregante piastrinica. Rilevante anche l’azione d’attivazione e potenziamento delle difese immunitarie, la modulazione neuroendocrina e circadiana, l’effetto sul midollo osseo con riflessi determinanti sulla crasi ematica, la dinamica midollare, la produzione di piastrine, globuli rossi e globuli bianchi. L’azione antitumorale diretta si attua inibendo la proliferazione e la crescita di cellule tumorali, ostacolando la tendenza di cellule normali a divenire neoplastiche inducendo il ricambio cellulare e la sostituzione di cellule tumorali con cellule sane attraverso il meccanismo definito “apoptosi”. E’ documentata anche un’azione antimetastatica attraverso l’inibizione della diffusione a distanza delle cellule tumorali unitamente alla capacità di migliorare in maniera significativa il profondo stato di decadimento psicofisico degli stadi tumorali avanzati comunemente definiti “cachessia neoplastica”.
Bibliografia:
Solo ricerca in vitro (organi isolati, tessuti, cellule o sistemi biochimici - definizione del libro d'oro IUPAC)
- 1988 Nov: Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture;
- 1990 Apr: Effects of the pineal hormone melatonin on the anchorage-independent growth of human breast cancer cells MCF-7 in a clonogenic culture system;
- 1990 Oct: Melatonin effects on the cytoskeletal organization of MDCK and neuroblastoma N1E-115 cells;
- 1991 Jan: Effects of melatonin on the cell cycle kinetics and "estrogen-rescue" of MCF-7 human breast cancer cells in culture;
- 1992 Jul: The growth inhibitory action of melatonin on human breast cancer cells is linked to the estrogen response system;
- 1993 Jan: Antiproliferative effect of pineal indoles on cultured tumor cell lines;
- 1993 Jul: Human malignant melanoma cells express high-affinity receptors for melatonin: antiproliferative effects of melatonin and 6-chloromelatonin;
- 1994 Mar: Pineal gland metastases from mammary carcinoma;
- 1994 May: Hematopoietic rescue via T-cell-dependent, endogenous granulocyte-macrophage colony-stimulating factor induced by the pineal neurohormone melatonin in tumor-bearing mice;
- 1994 May: Interaction between melatonin and estradiol on morphological and morphometric features of MCF-7 human breast cancer cells;
- 1994 Dec: Modulation of estrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells;
- 1995 Jan: Melatonin protects human blood lymphocytes from radiation-induced chromosome damage;
- 1995 Mar: Melatonin modulation of estrogen-regulated proteins, growth factors, and proto-oncogenes in human breast cancer;
- 1995 May: Melatonin's inhibitory effect on growth of ME-180 human cervical cancer cells is not related to intracellular glutathione concentrations;
- 1995 Jul: Marked reduction of radiation-induced micronuclei in human blood lymphocytes pretreated with melatonin;
- 1995 Jul: Melatonin inhibition of MCF-7 human breast-cancer cells growth: influence of cell proliferation rate;
- 1995 Dec: Melatonin blocks the stimulatory effects of prolactin on human breast cancer cell growth in culture;
- 1996 Jan: Modulation of the length of the cell cycle time of MCF-7 human breast cancer cells by melatonin;
- 1996 Apr: Functional melatonin receptors in human prostate epithelial cells;
- 1996 May: Melatonin inhibits DNA synthesis in MCF-7 human breast cancer cells in vitro;
- 1996 Jun: Effect of melatonin on beta-tubulin and MAP2 expression in NIE-115 cells.
- 1996 Sep: Effects of melatonin on the proliferation and differentiation of human neuroblastoma cells in culture;
- 1996 Dec: Melatonin and radioprotection from genetic damage: in vivo/in vitro studies with human volunteers;
- 1997 Jun: Effects of melatonin on proliferation, oxidative stress and Cx32 gap junction protein expression in primary cultures of adult rat hepatocytes;
- 1998 Feb: Melatonin reduces gamma radiation-induced primary DNA damage in human blood lymphocytes;
- 1998 Jun: A sequential treatment regimen with melatonin and all-trans retinoic acid induces apoptosis in MCF-7 tumour cells;
- 1998 Jun: Estrogen receptor transactivation in MCF-7 breast cancer cells by melatonin and growth fractors;
- 1998 Aug: Topical melatonin in combination with vitamins E and C protects skin from ultraviolet-induced erythema: a human study in vivo;
- 1998 Oct: Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells;
- 1999 ???: The antiproliferative effects of melatonin on experimental pituitary and colonic tumors. Possible involvement of the putative nuclear binding site?;
- 1999 Jun: Melatonin increases p53 and p21WAF1 expression in MCF-7 human breast cancer cells in vitro;
- 1999 Jul: Melatonin promotes osteoblast differentiation and bone formation;
- 2000 Jan-Feb: In vitro effects of melatonin on cell proliferation in a colon adenocarcinoma line;
- 2000 Mar: Antiproliferative action of melatonin on human prostate cancer LNCaP cells;
- 2000 Apr: Influence of melatonin on proliferation and antioxidant system in Ehrlich ascites carcinoma cells;
- 2000 May: Differential growth inhibitory effect of melatonin on two endometrial cancer cell lines;
- 2000 Jun: Pathways through which a regimen of melatonin and retinoic acid induces apoptosis in MCF-7 human breast cancer cells;
- 2000 Oct: Melatonin effects on intercellular junctional communication in MCF-7 human breast cancer cells;
- 2000 Nov: Growth-inhibitory activity of melatonin on human androgen-independent DU 145 prostate cancer cells;
- 2001 Jan: Inhibition of androgen-sensitive LNCaP prostate cancer growth in vivo by melatonin: association of antiproliferative action of the pineal hormone with mt1 receptor protein expression;
- 2001 Jan: N1E-115 mouse neuroblastoma cells express MT1 melatonin receptors and produce neurites in response to melatonin;
- 2001 Apr: Direct antiproliferative effects of melatonin on two metastatic cell sublines of mouse melanoma (B16BL6 and PG19);
- 2001 May: Transcriptional repression of RORalpha activity in human breast cancer cells by melatonin;
- 2001 Jul: Melatonin reduces X-ray irradiation-induced oxidative damages in cultured human skin fibroblasts;
- 2001 Aug: Prooxidant Activity of Melatonin Promotes Fas-Induced Cell Death in Human Leukemic Jurkat Cells;
- 2001 Oct: Melatonin elicits nuclear exclusion of the human androgen receptor and attenuates its activity;
- 2001 Nov: Cyclical regulation of GnRH gene expression in GT1-7 GnRH-secreting neurons by melatonin;
- 2001 Dec: Evaluation of signal transduction pathways mediating the nuclear exclusion of the androgen receptor by melatonin;
- 2002 Jan: Melatonin inhibits estrogen receptor transactivation and cAMP levels in breast cancer cells;
- 2002 Mar: Modulation of intracellular calcium and calmodulin by melatonin in MCF-7 human breast cancer cells;
- 2002 Apr: Differential regulation by melatonin of cell growth and androgen receptor binding to the androgen response element in prostate cancer cells;
- 2002 Apr: Effects of melatonin and melatonin receptors ligand N-[(4-methoxy-1H-indol-2-yl)methyl]propanamide on murine Colon 38 cancer growth in vitro and in vivo;
- 2002 May: Involvement of the mt1 melatonin receptor in human breast cancer;
- 2002 May: Nuclear exclusion of the androgen receptor by melatonin;
- 2002 Jun: MT(1) melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells;
- 2002 Sep: Differential expression of high-affinity melatonin receptors (MT1) in normal and malignant human breast tissue;
- 2002 Dec: Melatonin effects on megakaryocyte membrane patch-clamp outward K+ current (Di Bella L. et al.);
- 2003 Feb: Melatonin enhances retinoic acid induction of cone arrestin gene expression in retinoblastoma cells;
- 2003 Apr: Melatonin and vitamin D3 increase TGF-beta1 release and induce growth inhibition in breast cancer cell cultures;
- 2003 Sep: Beta-amyloid modulates tyrosine kinase B receptor expression in SHSY5Y neuroblastoma cells: influence of the antioxidant melatonin;
- 2003 Sep: Melatonin binding sites in estrogen receptor-positive cells derived from human endometrial cancer;
- 2003 Oct: Melatonin inhibits telomerase activity in the MCF-7 tumor cell line both in vivo and in vitro;
- 2003 Oct: Melatonin slowed the early biochemical progression of hormone-refractory prostate cancer in a patient whose prostate tumor tissue expressed MT1 receptor subtype;
- 2005 Mar: Melatonin modulates aromatase activity in MCF-7 human breast cancer cells;
- 2005 Apr: Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism;
- 2005 May: Differential regulation of estrogen receptor alpha, glucocorticoid receptor and retinoic acid receptor alpha transcriptional activity by melatonin is mediated via different G proteins;
- 2005 Aug: Modulation by melatonin of the cardiotoxic and antitumor activities of adriamycin;
- 2005 Oct: Biotransformation of melatonin in human breast cancer cell lines: role of sulfotransferase 1A1;
- 2005 Oct: Melatonin enhances the inhibitory effect of aminoglutethimide on aromatase activity in MCF-7 human breast cancer cells;
- 2005 Nov: Melatonin provokes cell death in human B-lymphoma cells by mitochondrial-dependent apoptotic pathway activation;
- 2006 Jan: Antiestrogens modulate MT1 melatonin receptor expression in breast and ovarian cancer cell lines;
- 2006 Jan: Intracellular signaling pathways involved in the cell growth inhibition of glioma cells by melatonin;
- 2006 Feb: Melatonin cytotoxicity in human leukemia cells: relation with its pro-oxidant effect;
- 2006 Jun: Assessment of the radioprotective effects of amifostine and melatonin on human lymphocytes irradiated with gamma-rays in vitro;
- 2006 Sep: Melatonin induces apoptosis in human neuroblastoma cancer cells;
- 2006 Sep: Oncostatic effects of the indole melatonin and expression of its cytosolic and nuclear receptors in cultured human melanoma cell lines;
- 2007 Mar: Inhibition of proliferation and induction of apoptosis by melatonin in human myeloid HL-60 cells;
- 2007 Mar: Melatonin inhibits nitric oxide production by microvascular endothelial cells in vivo and in vitro;
- 2007 Apr: Effects of MT1 melatonin receptor overexpression on the aromatase-suppressive effect of melatonin in MCF-7 human breast cancer cells;
- 2007 Apr: Melatonin at pharmacological doses enhances human osteoblastic differentiation in vitro and promotes mouse cortical bone formation in vivo;
- 2007 May-Jun: Effect of melatonin on cytotoxicity of doxorubicin toward selected cell lines (human keratinocytes, lung cancer cell line A-549, laryngeal cancer cell line Hep-2);
- 2007 Aug: Melatonin stimulates HSP27 phosphorylation in human pancreatic carcinoma cells (PANC-1);
- 2007 Sep: Cellular mechanisms involved in the melatonin inhibition of HT-29 human colon cancer cell proliferation in culture;
- 2007 Sep: Expression of the melatonin receptor (MT) 1 in benign and malignant human bone tumors;
- 2007 Sep: Inhibitory effects of pharmacological doses of melatonin on aromatase activity and expression in rat glioma cells;
- 2007 Oct: Involvement of protein kinase C in melatonin's oncostatic effect in C6 glioma cells;
- 2008 Mar: Melatonin modulates the expression of VEGF and HIF-1 alpha induced by CoCl2 in cultured cancer cells;
- 2008 Apr: Frequent silencing of a putative tumor suppressor gene melatonin receptor 1 A (MTNR1A) in oral squamous-cell carcinoma;
- 2008 May: Melatonin down-regulates hTERT expression induced by either natural estrogens (17beta-estradiol) or metalloestrogens (cadmium) in MCF-7 human breast cancer cells;
- 2008 Aug: Melatonin modulates the cadmium-induced expression of MT-2 and MT-1 metallothioneins in three lines of human tumor cells (MCF-7, MDA-MB-231 and HeLa);
- 2008 Aug: Expression of melatonin receptor (MT1) and interaction between melatonin and estrogen in endometrial cancer cell line;
- 2008 Aug: Selective estrogen enzyme modulator actions of melatonin in human breast cancer cells;
- 2008 Aug: The antiproliferative activity of melatonin in B65 rat dopaminergic neuroblastoma cells is related to the downregulation of cell cycle-related genes;
- 2008 Oct: Critical role of glutathione in melatonin enhancement of tumor necrosis factor and ionizing radiation-induced apoptosis in prostate cancer cells in vitro;
- 2008 Nov: Melatonin induces cell cycle arrest and apoptosis in hepatocarcinoma HepG2 cell line;
- 2009 Feb: The effects of melatonin on human hepatoma (Hep G2) cell line;
- 2009 Mar: Evidence for a biphasic apoptotic pathway induced by melatonin in MCF-7 breast cancer cells;
- 2009 May: Coexpression of the melatonin receptor 1 and nestin in human breast cancer specimens;
- 2009 May: Melatonin down-regulates HIF-1 alpha expression through inhibition of protein translation in prostate cancer cells;
- 2009 May: Melatonin induces mitochondrial-mediated apoptosis in human myeloid HL-60 cells;
- 2009 Aug: Intracellular prooxidant activity of melatonin induces a survival pathway involving NF-kappaB activation;
- 2009 Aug: Melatonin as a modulator of apoptosis in B-lymphoma cells;
- 2009 Aug: Melatonin induces apoptotic death in LNCaP cells via p38 and JNK pathways: therapeutic implications for prostate cancer;
- 2009 Aug: Membrane-bound melatonin receptor MT1 down-regulates estrogen responsive genes in breast cancer cells;
- 2009 Aug: Neuroprotection by melatonin on astrocytoma cell death;
- 2009 Sep: Melatonin exerts differential actions on X-ray radiation-induced apoptosis in normal mice splenocytes and Jurkat leukemia cells;
- 2009 Oct: The expression of MT1 melatonin receptor and Ki-67 antigen in melanoma malignum;
- 2009 Nov: Changes in the expression of melatonin receptors induced by melatonin treatment in hepatocarcinoma HepG2 cells;
- 2009 Nov: Melatonin inhibits aromatase promoter expression by regulating cyclooxygenases expression and activity in breast cancer cells;
- 2009 Dec: Molecular mechanisms of melatonin anticancer effects;
- 2010 Jan: Inhibition of procarcinogen-bioactivating human CYP1A1, CYP1A2 and CYP1B1 enzymes by melatonin;
- 2010 Jan: Melatonin sensitizes human malignant glioma cells against TRAIL-induced cell death;
- 2010 Jan: Synergistic antitumor effect of melatonin with several chemotherapeutic drugs on human Ewing sarcoma cancer cells: potentiation of the extrinsic apoptotic pathway;
- 2010 Mar: Melatonin and doxorubicin synergistically induce cell apoptosis in human hepatoma cell lines;
- 2010 Apr: Inhibitory effects of melatonin on sulfatase and 17beta-hydroxysteroid dehydrogenase activity and expression in glioma cells;
- 2010 Apr: Signal transduction of the melatonin receptor MT1 is disrupted in breast cancer cells by electromagnetic fields;
- 2010 Jun: Melatonin inhibits mitogenic cross-talk between retinoic acid-related orphan receptor alpha (RORalpha) and ERalpha in MCF-7 human breast cancer cells;
- 2010 Aug: Melatonin decreases cell proliferation and induces melanogenesis in human melanoma SK-MEL-1 cells;
- 2010 Aug: Melatonin resynchronizes dysregulated circadian rhythm circuitry in human prostate cancer cells;
- 2010 Sep-Oct: Psychoneuroendocrine modulation of regulatory T lymphocyte system: in vivo and in vitro effects of the pineal immunomodulating hormone melatonin;
- 2010 Oct: In vitro and in vivo antitumor activity of melatonin receptor agonists;
- 2010 Oct: Melatonin induces pro-apoptotic signaling pathway in human pancreatic carcinoma cells (PANC-1);
- 2010 Oct: Signal transduction of receptor-mediated antiproliferative action of melatonin on human prostate epithelial cells involves dual activation of Gα(s) and Gα(q) proteins;
- 2010 Nov: Melatonin and vitamin D3 synergistically down-regulate Akt and MDM2 leading to TGFβ-1-dependent growth inhibition of breast cancer cells;
- 2010 Dec: Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathway;
- 2010 Dec: Melatonin Induces Apoptotic Cell Death via p53 in LNCaP Cells;
- 2011 Jan: Pro-oxidant effect of melatonin in tumour leucocytes: relation with its cytotoxic and pro-apoptotic effects;
- 2011 Mar: Melatonin, a novel Sirt1 inhibitor, imparts antiproliferative effects against prostate cancer in vitro in culture and in vivo in TRAMP model;
- 2011 Mar: Melatonin and vitamin D3 synergistically down-regulate Akt and MDM2 leading to TGFβ-1-dependent growth inhibition of breast cancer cells;
- 2011 Mar: Melatonin enhances the in vitro action of cytochalasin B on globular resistance and osmotic fragility of erythrocytes;
- 2011 Apr: Melatonin receptors, melatonin metabolizing enzymes and cyclin D1 in human breast cancer;
- 2011 Apr: Melatonin reduces pancreatic tumor cell viability by altering mitochondrial physiology;
- 2011 May: Molecular basis for defining the pineal gland and pinealocytes as targets for tumor necrosis factor;
- 2011 Jun: Melatonin protects human cells from clustered DNA damages, killing and acquisition of soft agar growth induced by X-rays or 970 MeV/n Fe ions;
- 2011 Jul: Melatonin enhances hydrogen peroxide-induced apoptosis in human promyelocytic leukaemia HL-60 cells;
- 2011 Jul: Melatonin promotes differentiation of 3T3-L1 fibroblasts;
- 2011 Oct: Functional interplay between melatonin receptor-mediated antiproliferative signaling and androgen receptor signaling in human prostate epithelial cells: potential implications for therapeutic strategies against prostate cancer;
- 2011 Oct: Melatonin exerts by an autocrine loop antiproliferative effects in cholangiocarcinoma: its synthesis is reduced favoring cholangiocarcinoma growth;
- 2011 Oct: Melatonin triggers p53Ser phosphorylation and prevents DNA damage accumulation;
- 2011 Oct: MicroRNA and gene expression analysis of melatonin-exposed human breast cancer cell lines indicating involvement of the anticancer effect;
- 2011 Nov: Intracellular redox state as determinant for melatonin antiproliferative vs cytotoxic effects in cancer cells;
- 2011 Nov: LNCaP Prostate Cancer Growth In Vivo: Oncostatic Effects of Melatonin as Compared to Hypoxia and Reoxygenation;
- 2011 Nov: Melatonin modulation of intracellular signaling pathways in hepatocarcinoma HepG2 cell line: role of the MT1 receptor;
- 2012 Mar: Fas/Fas ligand regulation mediates cell death in human Ewing's sarcoma cells treated with melatonin;
- 2012 Mar: Induction of cell differentiation and promotion of endocan gene expression in stomach cancer by melatonin;
- 2012 Apr: Combined effects of melatonin and all-trans retinoic acid and somatostatin on breast cancer cell proliferation and death: molecular basis for the anticancer effect of these molecules;
- 2012 Apr: Melatonin interferes in the desmoplastic reaction in breast cancer by regulating cytokine production;
- 2012 Apr: Melatonin suppresses aromatase expression and activity in breast cancer associated fibroblasts;
- 2012 May: Melatonin inhibits cell proliferation and induces caspase activation and apoptosis in human malignant lymphoid cell lines;
- 2012 Jul: Glia-pinealocyte network: the paracrine modulation of melatonin synthesis by tumor necrosis factor (TNF);
- 2012 Aug: Gender-related invasion differences associated with mRNA expression levels of melatonin membrane receptors in colorectal cancer;
- 2012 Aug: Melatonin potentiates chemotherapy-induced cytotoxicity and apoptosis in rat pancreatic tumor cells;
- 2012 Aug: Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells;
- 2012 Sep: Melatonin suppresses migration and invasion via inhibition of oxidative stress pathway in glioma cells;
- 2012 Oct: http://beatingcancercenter.com/2012-11-24-22-19-50/related-researches/2010/3384-melatonin-modulates-apoptosis-and-trpm2-channels-in-transfected-cells-activated-by-oxidative-stress.html;
- 2012 Oct: Novel Melatonin-chitosan Hydrogels as Suitable Oral Bio-drug Delivery Systems to Fight Oral Mucositis: Synergy of Antioxidants and Bioactives in Action;
- 2012 Dec: Melatonin inhibits the expression of vascular endothelial growth factor in pancreatic cancer cells;
- 2013 Jan: Genome-wide profiling in melatonin-exposed human breast cancer cell lines identifies differentially methylated genes involved in the anticancer effect of melatonin;
- 2013 Jan: Melatonin enhances DNA repair capacity possibly by affecting genes involved in DNA damage responsive pathways;
- 2013 Jan: Melatonin MT1 receptor-induced transcriptional up-regulation of p27(Kip1) in prostate cancer antiproliferation is mediated via inhibition of constitutively active nuclear factor kappa B (NF-κB): potential implications on prostate cancer chemoprevention and therapy;
- 2013 Jan: Phenotypic changes caused by melatonin increased sensitivity of prostate cancer cells to cytokine-induced apoptosis;
- 2013 Feb: Melatonin induces transcriptional regulation of Bim by FoxO3a in HepG2 cells;
- 2013 Mar: Antiangiogenic effects of melatonin in endothelial cell cultures;
- 2013 Mar: Melatonin inhibits cell growth and migration, but promotes apoptosis in gastric cancer cell line, SGC7901;
- 2013 Mar: Melatonin is involved in the apoptosis and necrosis of pancreatic cancer cell line SW-1990 via modulating of Bcl-2/Bax balance;
- 2013 Apr: Expression of melatonin receptor MT1 in cells of human invasive ductal breast carcinoma;
- 2013 Apr: Melatonin Suppresses the Expression of 45S Preribosomal RNA and Upstream Binding Factor and Enhances the Antitumor Activity of Puromycin in MDA-MB-231 Breast Cancer Cells;
- 2013 May: Blockage of melatonin receptors impairs p53-mediated prevention of DNA damage accumulation;
- 2013 May: Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells;
- 2013 May: Melatonin modulates aromatase activity and expression in endothelial cells;
- 2013 May: Regulation of vascular endothelial growth factor by melatonin in human breast cancer cells;
- 2013 May: SIRT1 inhibition by melatonin exerts antitumor activity in human osteosarcoma cells;
- 2013 Jun: Growth-inhibitory activity of melatonin on murine foregastric carcinoma cells in vitro and the underlying molecular mechanism;
- 2013 Jun: Melatonin induces apoptosis through a caspase-dependent but reactive oxygen species-independent mechanism in human leukemia Molt-3 cells;
- 2013 Jun: Melatonin treatment increases the transcription of cell proliferation-related genes prior to inducing cell death in C6 glioma cells in vitro;
- 2013 Jul: Inhibition of VEGF expression through blockade of Hif1α and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells;
- 2013 Jul: The modulatory effect of melatonin on genotoxicity of irinotecan in healthy human lymphocytes and cancer cells;
- 2013 Aug: Insulin and IGF1 enhance IL-17-induced chemokine expression through a GSK3B-dependent mechanism: a new target for melatonin's anti-inflammatory action;
- 2013 Aug: Melatonin inhibits the proliferation of human osteosarcoma cell line MG-63;
- 2013 Sep: Melatonin/PGC1A/UCP1 promotes tumor slimming and represses tumor progression by initiating autophagy and lipid browning;
- 2013 Sep: Melatonin overcomes apoptosis resistance in human hepatocellular carcinoma by targeting survivin and XIAP;
- 2013 Dec: Evaluation of inhibitory effect of melatonin on gastric adenocarcinoma AGS and MKN45 cell lines - (Only Persian Language - Abstract in English)
- 2013 Sep: Melatonin antagonizes hypoxia-mediated glioblastoma cell migration and invasion via inhibition of HIF-1α;
- 2014 Jan: Inhibition of matrix metalloproteinase-9 and nuclear factor kappa B contribute to melatonin prevention of motility and invasiveness in HepG2 liver cancer cells;
- 2014 Mar: Expression of MT2 receptor in patients with gastric adenocarcinoma and its relationship with clinicopathological features;
- 2014 Mar: Melatonin combined with endoplasmic reticulum stress induces cell death via the PI3K/Akt/mTOR pathway in B16F10 melanoma cells;
- 2014 Apr: Melatonin prevents chemical-induced haemopoietic cell death;
- 2014 Apr: Melatonin treatment induces interplay of apoptosis, autophagy, and senescence in human colorectal cancer cells;
- 2014 May: Melatonin reduces endothelin-1 expression and secretion in colon cancer cells through the inactivation of FoxO-1 and NF-κβ;
- 2014 Jul: Melatonin Inhibits the Migration of Human Lung Adenocarcinoma A549 Cell Lines Involving JNK/MAPK Pathway;
- 2014 Aug: Molecular markers of angiogenesis and metastasis in lines of oral carcinoma after treatment with melatonin;
- 2014 Oct: Immunomodulatory effect of melatonin in SK-LU-1 human lung adenocarcinoma cells co-cultured with peripheral blood mononuclear cells;
- 2014 Oct: Involvement of autophagy in melatonin-induced cytotoxicity in glioma-initiating cells;
- 2014 Oct: Melatonin induces apoptosis through biomolecular changes, in SK-LU-1 human lung adenocarcinoma cells;
- 2014 Nov: Melatonin promotes osteoblast differentiation and mineralization of MC3T3-E1 cells under hypoxic conditions through activation of PKD/p38 pathways;
- 2015 Jan: Melatonin induces apoptosis in cholangiocarcinoma cell lines by activating the reactive oxygen species-mediated mitochondrial pathway;
- 2015 Jan: Upregulation of miRNA3195 and miRNA374b Mediates the Anti-Angiogenic Properties of Melatonin in Hypoxic PC-3 Prostate Cancer Cells;
- 2015 Feb: Melatonin potentiates cisplatin-induced apoptosis and cell cycle arrest in human lung adenocarcinoma cells;
- 2015 Mar: Comparison of the Effects of 13-cis Retinoic Acid and Melatonin on the Viabilities of SH-SY5Y Neuroblastoma Cell Line;
- 2015 Mar: Human gastroenteropancreatic expression of melatonin and its receptors MT1 and MT2;
- 2015 Mar: Involvement of ROS-alpha v Beta 3 integrin-FAK/Pyk2 in the Inhibitory Effect of Melatonin on U251 Glioma Cell Migration and Invasion Under Hypoxia;
- 2015 Mar: Melatonin sensitizes human breast cancer cells to ionizing radiation by downregulating proteins involved in double-strand DNA break repair;
- 2015 Mar: Melatonin uptake through glucose transporters: a new target for melatonin inhibition of cancer;
- 2015 Apr: Effects of melatonin combined with Cis-platinum or methotrexate on the proliferation of osteosarcoma cell line SaOS-2;
- 2015 Apr: Expression of melatonin receptors genes and genes associated with regulation of their activity in endometrial cancer - (Only Polish Language - Abstract in English);
- 2015 May: Evidence for Biphasic Effects and Differential Expression of Melatonin (MLT) Receptors in Oral Squamous Cell Carcinomas;
- 2015 May: Melatonin antiproliferative effects require active mitochondrial function in embryonal carcinoma cells;
- 2015 May: Melatonin induces apoptosis of colorectal cancer cells through HDAC4 nuclear import mediated by CaMKII inactivation;
- 2015 Jun: Melatonin attenuates oxidative damage induced by Acrylamide in vitro and in vivo;
- 2015 Jul: Melatonin affects voltage-dependent calcium and potassium currents in MCF-7 cell line cultured either in growth or differentiation medium;
- 2015 Aug: Melatonin Cytotoxicity Is Associated to Warburg Effect Inhibition in Ewing Sarcoma Cells;
- 2015 Sep: Ceramide metabolism regulates autophagy and apoptotic cell death induced by melatonin in liver cancer cells;
- 2015 Sep: Involvement of nuclear receptor RZR/RORγ in melatonin-induced HIF-1α inactivation in SGC-7901 human gastric cancer cells;
- 2015 Sep: Melatonin induces antiproliferative activity through modulation of apoptotic pathway in H-ras oncogene transformed 5RP7 cells;
- 2015 Sep: Melatonin inhibits the Migration of Colon Cancer RKO cells by Down-regulating Myosin Light Chain Kinase Expression through Cross-talk with p38 MAPK;
- 2015 Sep: Oncostatic effect of melatonin in head and neck cancer cells: clonogenic assay;
- 2015 Oct: HDAC1 inhibition by melatonin leads to suppression of lung adenocarcinoma cells via induction of oxidative stress and activation of apoptotic pathways;
- 2015 Oct-Dec: The profile of melatonin receptors gene expression and genes associated with their activity in colorectal cancer: a preliminary report;
- 2015 Nov: Melatonin Enhances Arsenic Trioxide-Induced Cell Death via Sustained Upregulation of Redd1 Expression in Breast Cancer Cells;
- 2015 Dec: Melatonin/HPβCD complex: Microwave synthesis, integration with chitosan scaffolds and inhibitory effects on MG-63CELLS;
- 2015 Dec: Melatonin Induces Cell Apoptosis in AGS Cells Through the Activation of JNK and P38 MAPK and the Suppression of Nuclear Factor-Kappa B: a Novel Therapeutic Implication for Gastric Cancer;
- 2015 Dec: Melatonin suppression of aerobic glycolysis (Warburg effect), survival signalling and metastasis in human leiomyosarcoma;
- 2016 Jan: Melatonin Suppresses the Growth of Ovarian Cancer Cell Lines (OVCAR-429 and PA-1) and Potentiates the Effect of G1 Arrest by Targeting CDKs;
- 2016 Jan: Melatonin decreases breast cancer metastasis by modulating Rho-associated kinase protein-1 expression;
- 2016 Jan: Melatonin enhancement of the radiosensitivity of human breast cancer cells is associated with the modulation of proteins involved in estrogen biosynthesis;
- 2016 Jan: Melatonin inhibits AP-2β/hTERT, NF-κB/COX-2 and Akt/ERK and activates caspase/Cyto C signaling to enhance the antitumor activity of berberine in lung cancer cells;
- 2016 Jan: Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activation;
- 2016 Jan: Melatonin sensitizes human cervical cancer HeLa cells to cisplatin-induced cytotoxicity and apoptosis: effects on oxidative stress and DNA fragmentation;
- 2016 Feb: Melatonin inhibits MMP-9 transactivation and renal cell carcinoma metastasis by suppressing Akt-MAPKs pathway and NF-κB DNA-binding activity;
- 2016 Feb: Melatonin Prevents Mitochondrial Damage Induced by Doxorubicin in Mouse Fibroblasts Through Ampk-Ppar Gamma-Dependent Mechanisms;
- 2016 Mar: Effect of Melatonin in Epithelial Mesenchymal Transition Markers and Invasive Properties of Breast Cancer Stem Cells of Canine and Human Cell Lines;
- 2016 Mar: Melatonin inhibits TPA-induced oral cancer cell migration by suppressing matrix metalloproteinase-9 activation through the histone acetylation;
- 2016 Mar: Multitargeting activity of miR-24 inhibits long-term melatonin anticancer effects;
- 2016 Apr: Sustained release of melatonin: A novel approach in elevating efficacy of tamoxifen in breast cancer treatment;
- 2016 Apr: Synergic Effects of Doxorubicin and Melatonin on Apoptosis and Mitochondrial Oxidative Stress in MCF-7 Breast Cancer Cells: Involvement of TRPV1 Channels;
- 2016 May: Effects of melatonin on HIF‐1α and VEGF expression and on the invasive properties of hepatocarcinoma cells;
- 2016 May: Melatonin decreases estrogen receptor binding to estrogen response elements sites on the OCT4 gene in human breast cancer stem cells;
- 2016 May: Melatonin prevents cytosolic calcium overload, mitochondrial damage and cell death due to toxically high doses of dexamethasone-induced oxidative stress in human neuroblastoma SH-SY5Y cells;
- 2016 Jul: Altered tryptophan metabolism in human meningioma;
- 2016 Jul: Melatonin promotes ATO-induced apoptosis in MCF-7 cells: Proposing novel therapeutic potential for breast cancer;
- 2016 Aug: Melatonin downregulates nuclear receptor RZR/RORγ expression causing growth-inhibitory and anti-angiogenesis activity in human gastric cancer cells in vitro and in vivo;
- 2016 Aug: Melatonin Represses Metastasis in Her2-Postive Human Breast Cancer Cells by Suppressing RSK2 Expression;
- 2016 Sep: Melatonin suppresses TPA-induced metastasis by downregulating matrix metalloproteinase-9 expression through JNK/SP-1 signaling in nasopharyngeal carcinoma;
- 2016 Oct: Melatonin enhances sensitivity to fluorouracil in oesophageal squamous cell carcinoma through inhibition of Erk and Akt pathway;
- 2016 Oct: Melatonin enhancement of the radiosensitivity of human breast cancer cells is associated with the modulation of proteins involved in estrogen biosynthesis;
- 2016 Oct: Melatonin reversed tumor necrosis factor-alpha-inhibited osteogenesis of human mesenchymal stem cells by stabilizing SMAD1 protein;
- 2016 Nov: Inhibition of ERK1/2 Signaling Pathway is Involved in Melatonin's Antiproliferative Effect on Human MG-63 Osteosarcoma Cells;
- 2016 Nov: Melatonin induces cell apoptosis in Mia PaCa-2 cells via the suppression of nuclear factor-κB and activation of ERK and JNK: A novel therapeutic implication for pancreatic cancer;
- 2016 Nov: Melatonin synergizes the chemotherapeutic effect of 5-fluorouracil in colon cancer by suppressing PI3K/AKT and NF-κB/iNOS signaling pathways;
- 2017 Jan: IGFBP3 and MAPK/ERK signaling mediates melatonin-induced antitumor activity in prostate cancer;
- 2017 Jan: Synergistic Cytotoxicity of Melatonin and New-generation Anticancer Drugs Against Leukemia Lymphocytes But Not Normal Lymphocytes;
- 2017 Jan: Targeting NF-κB/AP-2β signaling to enhance antitumor activity of cisplatin by melatonin in hepatocellular carcinoma cells;
- 2017 Jan: The Impact of Different Extracellular Matrices on Melatonin Effect in Proliferation and Stemness Properties of Ovarian Cancer Cells;
- 2017 Feb: Melatonin Inhibits Glioblastoma Stem-like cells through Suppression of EZH2-NOTCH1 Signaling Axis;
- 2017 Feb: Melatonin treatment induces apoptosis through regulating the nuclear factor-κB and mitogen-activated protein kinase signaling pathways in human gastric cancer SGC7901 cells;
- 2017 Mar: Inhibition of VEGF-Induced VEGFR-2 Activation and HUVEC Migration by Melatonin and Other Bioactive Indolic Compounds;
- 2017 Apr: Melatonin and its metabolites protect human melanocytes against UVB-induced damage: Involvement of NRF2-mediated pathways;
- 2017 May: Melatonin Inhibits Androgen Receptor Splice Variant-7 (AR-V7)-Induced Nuclear Factor-Kappa B (NF-κB) Activation and NF-κB Activator-Induced AR-V7 Expression in Prostate Cancer Cells: Potential Implications for the Use of Melatonin in Castration-Resistant Prostate Cancer (CRPC) Therapy;
- 2017 May: VPA and MEL induce apoptosis by inhibiting the Nrf2-ARE signaling pathway in TMZ-resistant U251 cells;
- 2017 Jun: AA-NAT, MT1 and MT2 Correlates with Cancer Stem-Like Cell Markers in Colorectal Cancer: Study of the Influence of Stage and p53 Status of Tumors;
- 2017 Jun: Amelioration of Dalton's lymphoma-induced angiogenesis by melatonin;
- 2017 Jun: The Impact of Melatonin on Colon Cancer Cells' Resistance to Doxorubicin in an in Vitro Study;
- 2017 Jul: Melatonin Decreases Glucose Metabolism in Prostate Cancer Cells: A 13 C Stable Isotope-Resolved Metabolomic Study;
- 2017 Jul: Melatonin promotes osteoblast differentiation by regulating Osterix protein stability and expression;
- 2017 Jul: Melatonin suppresses hepatocellular carcinoma progression via lncRNA-CPS1-IT-mediated HIF-1α inactivation;
- 2017 Aug: Antiproliferative and Pro-Apoptotic Activity of Melatonin Analogues on Melanoma and Breast Cancer Cells;
- 2017 Sep: Melatonin at pharmacological concentrations suppresses osteoclastogenesis via the attenuation of intracellular ROS;
- 2017 Sep: Melatonin inhibits proliferation and invasion via repression of miRNA-155 in glioma cells;
- 2017 Oct: Impressive Suppression of Colon Cancer Growth by Triple Combination SN38/EF24/Melatonin: "Oncogenic" Versus "Onco-Suppressive" Reactive Oxygen Species;
- 2017 Nov: Melatonin enhances the apoptotic effects and modulates the changes in gene expression induced by docetaxel in MCF‑7 human breast cancer cells;
- 2017 Nov: Oxyprenylated Phenylpropanoids Bind to MT1 Melatonin Receptors and Inhibit Breast Cancer Cell Proliferation and Migration;
- 2017 Dec: A New Drug Effective on Human Ovarian and Prostate Cancer Cell Viability: Agomelatine;
- 2017 Dec: Melatonin inhibits colon cancer RKO cell migration by downregulating Rho‑associated protein kinase expression via the p38/MAPK signaling pathway;
- 2017 Dec: The potential therapeutic effect of melatonin on human ovarian cancer by inhibition of invasion and migration of cancer stem cells;
- 2018 Feb: The melatonin-MT1 receptor axis modulates tumor growth in PTEN-mutated gliomas;
- 2018 Mar: Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells;
- 2018 Mar: Melatonin Inhibits Reactive Oxygen Species-Driven Proliferation, Epithelial-Mesenchymal Transition, and Vasculogenic Mimicry in Oral Cancer;
- 2018 Mar: Melatonin Inhibits the Proliferation of Gastric Cancer Cells Through Regulating the miR-16-5p-Smad3 Pathway;
- 2018 Mar: Melatonin suppresses thyroid cancer growth and overcomes radioresistance via inhibition of p65 phosphorylation and induction of ROS;
- 2018 Apr: Combination of melatonin and rapamycin for head and neck cancer therapy: Suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation;
- 2018 Apr: Melatonin induces the apoptosis and inhibits the proliferation of human gastric cancer cells via blockade of the AKT/MDM2 pathway;
- 2018 Apr: Melatonin Promotes Apoptosis of Oxaliplatin-resistant Colorectal Cancer Cells Through Inhibition of Cellular Prion Protein;
- 2018 Apr: Modified in vitro release of the chronobiotic hormone melatonin from matrix tablets based on the marine sulfated polysaccharide ulvan;
- 2018 Apr: The protective role of melatonin in cadmium-induced proliferation of ovarian cancer cells;
- 2018 May : Dose-dependent proliferative and cytotoxic effects of melatonin on human epidermoid carcinoma and normal skin fibroblast cells;
- 2018 May: Increase in motility and invasiveness of MCF7 cancer cells induced by nicotine is abolished by melatonin through inhibition of ERK phosphorylation;
- 2018 May: Melatonin and its metabolite N1-acetyl-N2-formyl-5-methoxykynuramine (afmk) enhance chemosensitivity to gemcitabine in pancreatic carcinoma cells (PANC-1);
- 2018 May: Melatonin attenuates osteosarcoma cell invasion by suppression of C-C motif chemokine ligand 24 through inhibition of the c-Jun N-terminal kinase pathway;
- 2018 May: Mitochondria Transcription Factor A: A Putative Target for the Effect of Melatonin on U87MG Malignant Glioma Cell Line;
- 2018 Jun: Do Anti-Oxidants Vitamin D3, Melatonin, and Alpha-Lipoic Acid Have Synergistic Effects with Temozolomide on Cultured Glioblastoma Cells?;
- 2018 Jun: Melatonin Synergizes with Sorafenib to Suppress Pancreatic Cancer via Melatonin Receptor and PDGFR-β/STAT3 Pathway;
- 2018 Jun: Synergistic effect of thymoquinone and melatonin against breast cancer implanted in mice;
- 2018 Aug: Melatonin and 5-fluorouracil co-suppress colon cancer stem cells by regulating cellular prion protein-Oct4 axis;
- 2018 Aug: Mitochondria Transcription Factor A: A Putative Target for the Effect of Melatonin on U87MG Malignant Glioma Cell Line;
- 2018 Sep: Melatonin Can Strengthen the Effect of Retinoic Acid in HL-60 Cells;
- 2018 Sep: Melatonin inhibits breast cancer cell invasion through modulating DJ-1/KLF17/ID-1 signaling pathway;
- 2018 Sep: Melatonin Inhibits the Progression of Hepatocellular Carcinoma through MicroRNA Let7i-3p Mediated RAF1 Reduction;
- 2018 Sep: Melatonin restrains angiogenic factors in triple-negative breast cancer by targeting miR-152-3p: In vivo and in vitro studies;
- 2018 Sep: Melatonin Sensitizes Hepatocellular Carcinoma Cells to Chemotherapy Through Long Non-Coding RNA RAD51-AS1-Mediated Suppression of DNA Repair;
- 2018 Oct: Melatonin inhibits epithelial‑to‑mesenchymal transition in gastric cancer cells via attenuation of IL‑1β/NF‑κB/MMP2/MMP9 signaling;
- 2018 Oct: Melatonin suppresses TLR9-triggered proinflammatory cytokine production in macrophages by inhibiting ERK1/2 and AKT activation;
- 2018 Oct: Melatonin-mediated downregulation of ZNF746 suppresses bladder tumorigenesis mainly through inhibiting the AKT-MMP-9 signaling pathway;
- 2018 Oct: Stimulatory Effect of Indolic Hormone on As2O3 Cytotoxicity in Breast Cancer Cells: NF-κB-dependent Mechanism of Action of Melatonin;
- 2018 Nov: Melatonin and Its Metabolites Ameliorate UVR-Induced Mitochondrial Oxidative Stress in Human MNT-1 Melanoma Cells;
- 2018 Nov: Melatonin reduces lung cancer stemness through inhibiting of PLC, ERK, p38, β-catenin, and Twist pathways;
- 2018 Dec: Melatonin inhibits the migration of human gastric carcinoma cells at least in part by remodeling tight junction;
- 2018 Dec: Melatonin restricts the viability and angiogenesis of vascular endothelial cells by suppressing HIF-1α/ROS/VEGF;
- 2018 Dec: Melatonin Sensitizes Human Colorectal Cancer Cells to γ-ray Ionizing Radiation In Vitro and In Vivo;
- 2018 Dec: Melatonin-mediated downregulation of thymidylate synthase as a novel mechanism for overcoming 5-fluorouracil associated chemoresistance in colorectal cancer cells;
- 2019 Jan: Inhibition of TFEB oligomerization by co-treatment of melatonin with vorinostat promotes the therapeutic sensitivity in glioblastoma and glioma stem cells;
- 2019 Jan: Melatonin: The smart molecule that differentially modulates autophagy in tumor and normal placental cells;
- 2019 Jan: Melatonin Alleviates Radiation-Induced Lung Injury via Regulation of miR-30e/NLRP3 Axis;
- 2019 Jan: Melatonin and Docosahexaenoic Acid Decrease Proliferation of PNT1A Prostate Benign Cells via Modulation of Mitochondrial Bioenergetics and ROS Production;
- 2019 Jan: Pan-cancer Genomic Analyses Reveal Prognostic and Immunogenic Features of the Tumor Melatonergic Microenvironment Across 14 Solid Cancer Types;
- 2019 Feb: Downregulation of AKT and MDM2, Melatonin Induces Apoptosis in AGS and MGC803 Cells;
- 2019 Feb: Melatonin Enhances Cisplatin and Radiation Cytotoxicity in Head and Neck Squamous Cell Carcinoma by Stimulating Mitochondrial ROS Generation, Apoptosis, and Autophagy;
- 2019 Feb: Melatonin regulates tumor aggressiveness under acidosis condition in breast cancer cell lines;
- 2019 Feb: Melatonin suppresses lung cancer metastasis by inhibition of epithelial-mesenchymal transition through targeting to Twist;
- 2019 Feb: Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits;
- 2019 Mar: Melatonin enhances TNF-α-mediated cervical cancer HeLa cells death via suppressing CaMKII/Parkin/mitophagy axis;
- 2019 Apr: Melatonin protects spermatogonia from the stress of chemotherapy and oxidation via eliminating reactive oxidative species;
- 2019 May: Differential MicroRNA Expression of miR-21 and miR-155 within Oral Cancer Extracellular Vesicles in Response to Melatonin;
- 2019 May: Histone deacetylase 9 downregulation decreases tumor growth and promotes apoptosis in non-small cell lung cancer after melatonin treatment;
- 2019 May: Melatonin enhances sorafenib-induced cytotoxicity in FLT3-ITD acute myeloid leukemia cells by redox modification;
- 2019 May: Structural basis of ligand recognition at the human MT1 melatonin receptor;
- 2019 May: XFEL structures of the human MT2 melatonin receptor reveal the basis of subtype selectivity;
- 2019 Jun: Epigenetic inhibition of the tumor suppressor ARHI by light at night-induced circadian melatonin disruption mediates STAT3-driven paclitaxel resistance in breast cancer;
- 2019 Jun: Melatonin down-regulates microRNA-10a and decreases invasion and migration of triple-negative breast cancer cells;
- 2019 Jun: MTNR1B loss promotes chordoma recurrence by abrogating melatonin-mediated β-catenin signaling repression;
- 2019 Jun: Pharmacological, Mechanistic, and Pharmacokinetic Assessment of Novel Melatonin-Tamoxifen Drug Conjugates as Breast Cancer Drugs;
- 2019 Jun: Role of transforming growth factor β1 in the inhibition of gastric cancer cell proliferation by melatonin in vitro and in vivo;
- 2019 Jul: Deciphering the Molecular Basis of Melatonin Protective Effects on Breast Cells Treated with Doxorubicin: TWIST1 a Transcription Factor Involved in EMT and Metastasis, a Novel Target of Melatonin;
- 2019 Jul: Evidence that melatonin downregulates Nedd4-1 E3 ligase and its role in cellular survival;
- 2019 Jul: Melatonin and (-)-Epigallocatechin-3-Gallate: Partners in Fighting Cancer;
- 2019 Jul: Melatonin Enhances the Usefulness of Ionizing Radiation: Involving the Regulation of Different Steps of the Angiogenic Process;
- 2019 Jul: Prognostic Impact of Melatonin Receptors MT1 and MT2 in Non-Small Cell Lung Cancer (NSCLC);
- 2019 Aug: Dietary melatonin attenuates chromium-induced lung injury via activating the Sirt1/Pgc-1α/Nrf2 pathway;
- 2019 Aug: Melatonin Modulation of Radiation and Chemotherapeutics-induced Changes on Differentiation of Breast Fibroblasts;
- 2019 Aug: Melatonin promotes neuroblastoma cell differentiation by activating hyaluronan synthase 3-induced mitophagy;
- 2019 Aug: Melatonin reduces inflammatory response in human intestinal epithelial cells stimulated by interleukin-1β;
- 2019 Sep: Different Effects of Melatonin on X-Rays-Irradiated Cancer Cells in a Dose-Dependent Manner;
- 2019 Oct: Melatonin exerts oncostatic capacity and decreases melanogenesis in human MNT-1 melanoma cells;
- 2019 Oct: NEDD9 Inhibition by miR-25-5p Activation Is Critically Involved in Co-Treatment of Melatonin- and Pterostilbene-Induced Apoptosis in Colorectal Cancer Cells;
- 2019 Nov: A ketogenic diet combined with melatonin overcomes cisplatin and vincristine drug resistance in breast carcinoma syngraft;
- 2019 Nov: Melatonin activates cell death programs for the suppression of uterine leiomyoma cell proliferation;
- 2019 Nov: Melatonin decreases in vitro viability and migration of spheres derived from CF41.Mg canine mammary carcinoma cells;
- 2019 Nov: The Therapeutic Effect of Melatonin on GC by Inducing Cell Apoptosis and Autophagy Induced by Endoplasmic Reticulum Stress;
- 2019 Dec: Inhibition of autophagy triggers melatonin-induced apoptosis in glioblastoma cells;
- 2019 Dec: Melatonin modifies tumor hypoxia and metabolism by inhibiting HIF-1α and energy metabolic pathway in the in vitro and in vivo models of breast cancer;
- 2019 Dec: Melatonin Regulates Breast Cancer Progression by the lnc010561/miR-30/FKBP3 Axis;
- 2020 Jan: Effects of miR-34b/miR-892a Upregulation and Inhibition of ABCB1/ABCB4 on Melatonin-Induced Apoptosis in VCR-Resistant Oral Cancer Cells;
- 2020 Jan: Melatonin Inhibits TE-1 Esophageal Cancer Cells Metastasis by Suppressing the NF-κB Signaling Pathway and Decreasing MMP-9;
- 2020 Jan: Melatonin triggers the anticancer potential of phenylarsine oxide via induction of apoptosis through ROS generation and JNK activation;
- 2020 Feb: Melatonin alleviates progression of uterine endometrial cancer by suppressing estrogen/ubiquitin C/SDHB-mediated succinate accumulation;
- 2020 Feb: Melatonin attenuates doxorubicin-induced cardiotoxicity through preservation of YAP expression;
- 2020 Feb: The role of melatonin on miRNAs modulation in triple-negative breast cancer cells;
- 2020 Mar: Melatonin Regulates Cisplatin Resistance and Glucose Metabolism Through Hippo Signaling in Hepatocellular Carcinoma Cells;
- 2020 Mar: Melatonin reverses nasopharyngeal carcinoma cisplatin chemoresistance by inhibiting the Wnt/β-catenin signaling pathway;
- 2020 Mar: Retinoic Acid-Related Orphan Receptor alpha 1 (RORα1) Induction of AKR1C3 Promotes MCF-7 Breast Cancer Cell Proliferation and Tamoxifen-Resistance which is Suppressed by Melatonin;
- 2020 Mar: Structure-based discovery of potent and selective melatonin receptor agonists;
- 2020 Mar: Usefulness of melatonin as complementary to chemotherapeutic agents at different stages of the angiogenic process;
- 2020 Apr: Extracellular Acidosis Promotes Metastatic Potency via Decrease of the BMAL1 Circadian Clock Gene in Breast Cancer;
- 2020 Apr: Melatonin Enhances Palladium-Nanoparticle-Induced Cytotoxicity and Apoptosis in Human Lung Epithelial Adenocarcinoma Cells A549 and H1229;
- 2020 Apr: Melatonin Treatment Combined with TGF-β Silencing Inhibits Epithelial- Mesenchymal Transition in CF41 Canine Mammary Cancer Cell Line;
- 2020 May: Melatonin-triggered Post-Transcriptional and Post-Translational Modifications of ADAMTS1 Coordinately Retard Tumorigenesis and Metastasis of Renal Cell Carcinoma;
- 2020 Jun: Inhibitory effect of melatonin on hypoxia-induced vasculogenic mimicry via suppressing epithelial-mesenchymal transition (EMT) in breast cancer stem cells;
- 2020 Jun: Melatonin inhibits human melanoma cells proliferation and invasion via cell cycle arrest and cytoskeleton remodeling;
- 2020 Jun: Novel Melatonin, Estrogen, and Progesterone Hormone Therapy Demonstrates Anti-Cancer Actions in MCF-7 and MDA-MB-231 Breast Cancer Cells;
- 2020 Jul: Jagged2 progressively increased expression from Stage I to III of Bladder Cancer and Melatonin-mediated downregulation of Notch/Jagged2 suppresses the Bladder Tumorigenesis via inhibiting PI3K/AKT/mTOR/MMPs signaling;
- 2020 Jul: Melatonin increases 5-flurouracil-mediated apoptosis of colorectal cancer cells through enhancing oxidative stress and downregulating survivin and XIAP;
- 2020 Jul: Melatonin Protects Against Apoptosis of Megakaryocytic Cells via Its Receptors and the AKT/mitochondrial/caspase Pathway;
- 2020 Jul: Transcriptomic analysis on the effects of melatonin in gastrointestinal carcinomas;
- 2020 Aug: Effects of melatonin to arecoline-induced reactive oxygen species production and DNA damage in oral squamous cell carcinoma;
- 2020 Aug: Melatonin restores neutrophil functions and prevents apoptosis amid dysfunctional glutathione redox system;
- 2020 Aug: Melatonin suppresses chronic restraint stress-mediated metastasis of epithelial ovarian cancer via NE/AKT/β-catenin/SLUG axis;
- 2020 Sep: Melatonin increases the chemosensitivity of diffuse large B-cell lymphoma cells to epirubicin by inhibiting P-glycoprotein expression via the NF-κB pathway;
- 2020 Sep: Melatonin synergizes BRAF-targeting agent dabrafenib for the treatment of anaplastic thyroid cancer by inhibiting AKT/hTERT signalling;
- 2020 Oct: Melatonin and doxorubicin co-delivered via a functionalized graphene-dendrimeric system enhances apoptosis of osteosarcoma cells;
- 2020 Oct-Dec: The inhibitory effect of melatonin on the proliferation of irradiated A549 cell line;
- 2020 Nov: Melatonin Can Modulate the Effect of Navitoclax (ABT-737) in HL-60 Cells;
- 2020 Nov: Melatonin derivatives combat with inflammation-related cancer by targeting the Main Culprit STAT3;
- 2020 Nov: Melatonin impedes prostate cancer metastasis by suppressing MMP-13 expression;
- 2020 Dec: Melatonin inhibiting the survival of human gastric cancer cells under ER stress involving autophagy and Ras-Raf-MAPK signalling;
- 2020 Dec: Melatonin Inhibits the Progression of Oral Squamous Cell Carcinoma via Inducing miR-25-5p Expression by Directly Targeting NEDD9;
- 2020 Dec: Melatonin prevents doxorubicin-induced cardiotoxicity through suppression of AMPKα2-dependent mitochondrial damage;
- 2020 Dec: The Increment of Genoprotective Effect of Melatonin due to "Autooptic" Effect versus the Genotoxicity of Mitoxantrone;
- 2021 Jan: Melatonin downregulates TRPC6, impairing store-operated calcium entry in triple negative breast cancer cells;
- 2021 Jan: Melatonin Increases the Anticancer Potential of Doxorubicin in Caco-2 Colorectal Cancer Cells;
- 2021 Jan: Melatonin inhibits proliferation and viability and promotes apoptosis in colorectal cancer cells via upregulation of the microRNA-34a/449a cluster;
- 2021 Jan: Melatonin interrupts osteoclast functioning and suppresses tumor-secreted RANKL expression: implications for bone metastases;
- 2021 Feb: A novel signature predicts recurrence risk and therapeutic response in breast cancer patients;
- 2021 Mar: Effects of melatonin on the toxicity and proliferation of human anaplastic thyroid cancer cell line;
- 2021 Mar: FGF19/FGFR4 signaling axis confines and switches the role of melatonin in head and neck cancer metastasis;
- 2021 Mar: Melatonin sensitizes esophageal cancer cells to 5‑fluorouracil via promotion of apoptosis by regulating EZH2 expression;
- 2021 Mar: The effects of melatonin and vitamin D3 on the gene expression of BCl-2 and BAX in MCF-7 breast cancer cell line;
- 2021 Apr: Cumulative Protective Effect of Melatonin and Indole-3-Propionic Acid against KIO 3-Induced Lipid Peroxidation in Porcine Thyroid;
- 2021 Apr: Differential and Overlapping Effects of Melatonin and Its Metabolites on Keratinocyte Function: Bioinformatics and Metabolic Analyses;
- 2021 Apr: Melatonin indirectly decreases gastric cancer cell proliferation and invasion via effects on cancer-associated fibroblasts;
- 2021 Apr: Melatonin Modulates the Antioxidant Defenses and the Expression of Proinflammatory Mediators in Pancreatic Stellate Cells Subjected to Hypoxia;
- 2021 Apr: Melatonin Targets Metabolism in Head and Neck Cancer Cells by Regulating Mitochondrial Structure and Function;
- 2021 May: Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer;
- 2021 Jun: Impact of Andrographolide and Melatonin Combinatorial Drug Therapy on Metastatic Colon Cancer Cells and Organoids;
- 2021 Jun: Induction of EnR stress by Melatonin enhances the cytotoxic effect of Lapatinib in HER2-positive breast cancer;
- 2021 Jun: Inhibition of TMPRSS4 mediated epithelial-mesenchymal transition is critically involved in antimetastatic effect of melatonin in colorectal cancers;
- 2021 Jun: Melatonin inhibits gallbladder cancer cell migration and invasion via ERK-mediated induction of epithelial-to-mesenchymal transition;
- 2021 Jun: Melatonin inhibits lipid accumulation to repress prostate cancer progression by mediating the epigenetic modification of CES1;
- 2021 Jul: Melatonin inhibits lung cancer development by reversing the Warburg effect via stimulating the SIRT3/PDH axis;
- 2021 Jul: Melatonin inhibits triple-negative breast cancer progression through the Lnc049808-FUNDC1 pathway;
- 2021 Aug: A novel melatonin-regulated lncRNA suppresses TPA-induced oral cancer cell motility through replenishing PRUNE2 expression;
- 2021 Aug: Combination of Melatonin and Zoledronic Acid Suppressed the Giant Cell Tumor of Bone in vitro and in vivo;
- 2021 Aug: Melatonin and hyperbaric oxygen therapies suppress colorectal carcinogenesis through pleiotropic effects and multifaceted mechanisms;
- 2021 Aug: Melatonin and its derivative disrupt cancer stem-like phenotypes of lung cancer cells via AKT downregulation;
- 2021 Aug: Melatonin Induces Autophagy via Reactive Oxygen Species-Mediated Endoplasmic Reticulum Stress Pathway in Colorectal Cancer Cells;
- 2021 Aug: Melatonin reduces inflammation in intestinal cells, organoids and intestinal explants;
- 2021 Aug: The role of melatonin in angio-miR-associated inhibition of tumorigenesis and invasion in human glioblastoma tumour spheroids;
- 2021 Sep: Anticancer effects of melatonin via regulating lncRNA JPX-Wnt/β-catenin signalling pathway in human osteosarcoma cells;
- 2021 Sep: Effects of melatonin receptor expression on prognosis and survival in oral squamous cell carcinoma patients;
- 2021 Sep: Melatonin and doxorubicin synergistically enhance apoptosis via autophagy-dependent reduction of AMPKα1 transcription in human breast cancer cells;
- 2021 Sep: Melatonin enhances radiofrequency-induced NK antitumor immunity, causing cancer metabolism reprogramming and inhibition of multiple pulmonary tumor development;
- 2021 Sep: Melatonin inhibits proliferation, migration, and invasion by inducing ROS-mediated apoptosis via suppression of the PI3K/Akt/mTOR signaling pathway in gallbladder cancer cells;
- 2021 Sep: Melatonin potentiates the cytotoxic effect of Neratinib in HER2 + breast cancer through promoting endocytosis and lysosomal degradation of HER2;
- 2021 Sep: Melatonin reduces proliferation and promotes apoptosis of bladder cancer cells by suppressing O-GlcNAcylation of cyclin-dependent-like kinase 5;
- 2021 Sep: Melatonin Suppresses Oral Squamous Cell Carcinomas Migration and Invasion through Blocking FGF19/FGFR 4 Signaling Pathway;
- 2021 Oct: Melatonin Analogues Potently Inhibit MAO-B and Protect PC12 Cells against Oxidative Stress;
- 2021 Oct: Melatonin modulates metabolic remodeling in HNSCC by suppressing MTHFD1L-formate axis;
- 2021 Nov: Activity of Melatonin Against Gastric Cancer Growth in a Chick Embryo Tumor Xenograft Model;
- 2021 Nov: Effects of melatonin on the Bisphenol-A- induced cytotoxicity and genetic toxicity in colon cancer cell lines, normal gingival cell lines, and bone marrow stem cell lines;
- 2021 Dec: Melatonin and verteporfin synergistically suppress the growth and stemness of head and neck squamous cell carcinoma through the regulation of mitochondrial dynamics;
- 2021 Dec: Melatonin induces apoptotic cell death through Bim stabilization by Sp1-mediated OTUD1 upregulation;
- 2022 Jan: Melatonin decreases androgen-sensitive prostate cancer growth by suppressing SENP1 expression;
- 2022 Jan: Melatonin is a potential oncostatic agent to inhibit HepG2 cell proliferation through multiple pathways;
- 2022 Feb: Melatonin inhibits growth and metastasis of MDA-MB-231 breast cancer cells by activating autophagy;
- 2022 Mar: An In vitro Study on the Protective Effect of Melatonin on Human Sperm Parameters Treated by Cadmium;
- 2022 Mar: Combination of melatonin with paclitaxel reduces the TLR4-mediated inflammatory pathway, PD-L1 levels, and survival of ovarian carcinoma cells;
- 2022 Mar: Melatonin Attenuates Dasatinib-Aggravated Hypoxic Pulmonary Hypertension via Inhibiting Pulmonary Vascular Remodeling;
- 2022 Apr: Melatonin promotes apoptosis of thyroid cancer cells via regulating the signaling of microRNA-21 (miR-21) and microRNA-30e (miR-30e);
- 2022 May: Calcium acts as a central player in melatonin antitumor activity in sarcoma cells;
- 2022 May: Melatonin Increases the Sensitivity of Osteosarcoma Cells to Chemotherapy Drug Cisplatin;
- 2022 Jul: Diosgenin promotes cisplatin-induced apoptosis through oxidative DNA damage in A549 non-small cell lung cells;
- 2022 Nov: Development of in vitro and in vivo tools to evaluate the antiangiogenic potential of melatonin to neutralize the angiogenic effects of VEGF and breast cancer cells: CAM assay and 3D endothelial cell spheroids;
- 2022 Nov: The ubiquitin-specific protease 8 antagonizes melatonin-induced endocytic degradation of MT1 receptor to promote lung adenocarcinoma growth.
In Vivo (Solo animale)
- 1974 Nov: Stimulation and suppression of somatomedin activity by serotonin and melatonin;
- 1979 ???: Perspectives in pineal functions (Di Bella L. et al.);
- 1986 Mar: Inhibitory effects of the pineal hormone melatonin and underfeeding during the promotional phase of 7,12-dimethylbenzanthracene-(DMBA)-induced mammary tumorigenesis;
- 1988 Mar: Pineal melatonin, its fundamental immunoregulatory role in aging and cancer;
- 1994 May: Hematopoietic rescue via T-cell-dependent, endogenous granulocyte-macrophage colony-stimulating factor induced by the pineal neurohormone melatonin in tumor-bearing mice;
- 1997 Mar: Effects of melatonin on mammary gland lesions in transgenic mice overexpressing N-ras proto-oncogene;
- 1997 Aug: Melatonin and colon carcinogenesis: I. Inhibitory effect of melatonin on development of intestinal tumors induced by 1,2-dimethylhydrazine in rats;
- 1998 Feb: The effect of melatonin chronic treatment upon macrophage and lymphocyte metabolism and function in Walker-256 tumour-bearing rats;
- 1998 Oct: Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells;
- 1999 ???: The antiproliferative effects of melatonin on experimental pituitary and colonic tumors. Possible involvement of the putative nuclear binding site?;
- 1999 Jan: Melatonin administration in tumor-bearing mice (intact and pinealectomized) in relation to stress, zinc, thymulin and IL-2;
- 1999 Jan: Melatonin and colon carcinogenesis. II. Intestinal melatonin-containing cells and serum melatonin level in rats with 1,2-dimethylhydrazine-induced colon tumors;
- 1999 Mar: Melatonin and protection from whole-body irradiation: survival studies in mice;
- 1999 Aug: Maternal and developmental toxicity evaluation of melatonin administered orally to pregnant Sprague-Dawley rats;
- 1999 Aug: Radioprotective effect of melatonin assessed by measuring chromosomal damage in mitotic and meiotic cells;
- 1999 Sep: Melatonin Inhibition of Cancer Growth in Vivo Involves Suppression of Tumor Fatty Acid Metabolism via Melatonin Receptor-mediated Signal Transduction Events;
- 1999 Nov: Melatonin and protection from genetic damage in blood and bone marrow: whole-body irradiation studies in mice;
- 2000 Mar: Melatonin and colon carcinogenesis. III. Effect of melatonin on proliferative activity and apoptosis in colon mucosa and colon tumors induced by 1,2-dimethylhydrazine in rats;
- 2000 Mar: Ototoxicity caused by cisplatin is ameliorated by melatonin and other antioxidants;
- 2000 Sep: Melatonin inhibits apoptosis during early B-cell development in mouse bone marrow;
- 2000 Nov-Dec: The protective effect of melatonin on cisplatin nephrotoxicity;
- 2001 Jan: Inhibition of androgen-sensitive LNCaP prostate cancer growth in vivo by melatonin: association of antiproliferative action of the pineal hormone with mt1 receptor protein expression;
- 2001 Mar: Comparison of the protective effect of melatonin with other antioxidants in the hamster kidney model of estradiol-induced DNA damage;
- 2002 Mar: Tumor prevention by 9-cis-retinoic acid in the N-nitroso-N-methylurea model of mammary carcinogenesis is potentiated by the pineal hormone melatonin;
- 2002 Apr: Effects of melatonin and melatonin receptors ligand N-[(4-methoxy-1H-indol-2-yl)methyl]propanamide on murine Colon 38 cancer growth in vitro and in vivo;
- 2002 May: The effect of melatonin on peripheral blood cells during total body irradiation in rats;
- 2002 Jul: Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity;
- 2003 Mar: Anti-oxidative Effects of Melatonin in Protection Against Renal tubular Damage Caused By Ionizing Radiation In Mice;
- 2003 Apr: Melatonin reduces lipid peroxidation and nitric oxide during irradiation-induced oxidative injury in the rat liver;
- 2003 Aug: The effect of melatonin against oxidative damage during total-body irradiation in rats;
- 2003 Sep: Protective effects of melatonin and vitamin E in brain damage due to gamma radiation: an experimental study;
- 2003 Oct: Melatonin inhibits telomerase activity in the MCF-7 tumor cell line both in vivo and in vitro;
- 2003 Nov: Protective effect of melatonin against fractionated irradiation-induced epiphyseal injury in a weanling rat model;
- 2003 Dec: Melatonin ameliorates ionizing radiation-induced oxidative organ damage in rats;
- 2004 Mar: Protective effects of melatonin on the ionizing radiation induced DNA damage in the rat brain;
- 2004 Sep: The profile of melatonin production in tumour-bearing rats;
- 2005 Feb: Ultrastructural evaluation of the radioprotective effects of melatonin against X-ray-induced skin damage in Albino rats;
- 2005 Apr: Preventive and curative effect of melatonin on mammary carcinogenesis induced by dimethylbenz[a]anthracene in the female Sprague-Dawley rat;
- 2005 Jun: Radioprotective effects of melatonin on radiation-induced cataract;
- 2005 Mar: The human MT1 melatonin receptor stimulates cAMP production in the human neuroblastoma cell line SH-SY5Y cells via a calcium-calmodulin signal transduction pathway;
- 2005 Aug: Modulation by melatonin of the cardiotoxic and antitumor activities of adriamycin;
- 2005 Nov: Protective effects of melatonin on gamma-ray induced intestinal damage;
- 2006 Jan: Intracellular signaling pathways involved in the cell growth inhibition of glioma cells by melatonin;
- 2006 Jan: Melatonin inhibits the growth of DMBA-induced mammary tumors by decreasing the local biosynthesis of estrogens through the modulation of aromatase activity;
- 2006 May: Effects of melatonin and vitamin E on oxidative-antioxidative status in rats exposed to irradiation;
- 2006 Jun: Ameliorative effect of melatonin against gamma-irradiation-induced oxidative stress and tissue injury;
- 2006 Jun: Effects of melatonin in reducing the toxic effects of doxorubicin;
- 2006 Jun: Melatonin prevents X-ray irradiation induced oxidative damagein peripheral blood and spleen of the seasonally breeding rodent, Funambulus pennanti during reproductively active phase;
- 2006 Jun: Morphological evaluation of the radioprotective effects of melatonin against X-ray-induced early and acute testis damage in Albino rats: an animal model;
- 2007 Mar: Melatonin inhibits nitric oxide production by microvascular endothelial cells in vivo and in vitro;
- 2007 Mar: The histopathological evaluation of the effectiveness of melatonin as a protectant against acute lung injury induced by radiation therapy in a rat model;
- 2007 Apr: Melatonin at pharmacological doses enhances human osteoblastic differentiation in vitro and promotes mouse cortical bone formation in vivo;
- 2007 Sep-Oct: Alpha-tocopherol, beta-carotene and melatonin administration protects cyclophosphamide-induced oxidative damage to bladder tissue in rats;
- 2007 Oct: Beneficial properties of melatonin in an experimental model of pancreatic cancer;
- 2007 Oct: Melatonin prevents inflammation and oxidative stress caused by abdominopelvic and total body irradiation of rat small intestine;
- 2008 Apr: Effects of exogenous melatonin and circadian synchronization on tumor progression in melanoma-bearing C57BL6 mice;
- 2008 May: Effect of exogenous melatonin on X-ray induced cellular toxicity in lymphatic tissue of Indian tropical male squirrel, Funambulus pennanti;
- 2008 Oct: Comparison of the protective effects of melatonin and amifostine on radiation-induced epiphyseal injury;
- 2008 Nov: Melatonin and roentgen irradiation-induced acute radiation enteritis in Albino rats: an animal model;
- 2009 Jan: Action of melatonin on bone marrow depression induced by cyclophosphamide in acute toxicity phase;
- 2009 Jan: Cranial irradiation-induced inhibition of neurogenesis in hippocampal dentate gyrus of adult mice: attenuation by melatonin pretreatment;
- 2009 Jan: Melatonin suppresses AOM/DSS-induced large bowel oncogenesis in rats;
- 2009 Jun: Melatonin prevents the development of hyperplastic urothelium induced by repeated doses of cyclophosphamide;
- 2009 Jun-Jul: Protection of rat chromosomes by melatonin against gamma radiation-induced damage;
- 2009 Feb: Comparative effect of melatonin and vitamin E on phenylhydrazine-induced toxicity in the spleen of Funambulus pennanti;
- 2009 Aug: Antineoplastic effects of melatonin on a rare malignancy of mesenchymal origin: melatonin receptor-mediated inhibition of signal transduction, linoleic acid metabolism and growth in tissue-isolated human leiomyosarcoma xenografts;
- 2009 Sep: Melatonin exerts differential actions on X-ray radiation-induced apoptosis in normal mice splenocytes and Jurkat leukemia cells;
- 2009 Sep: Potential chemoprotective effect of melatonin in cyclophosphamide- and cisplatin-induced testicular damage in rats;
- 2009 Oct: Immunohistochemical study for the expression of Bcl-2 family proteins in Walker 256 carcinosarcoma cells under the influence of cytostatic drugs;
- 2009 Nov: Evaluation of Melatonin for Prevention of Radiation Myelopathy in Irradiated Cervical Spinal Cord;
- 2009 Dec: Circadian stage-dependent inhibition of human breast cancer metabolism and growth by the nocturnal melatonin signal: consequences of its disruption by light at night in rats and women;
- 2009 Dec: Molecular mechanisms of melatonin anticancer effects;
- 2010 Feb: Long-term melatonin administration attenuates low-LET gamma-radiation-induced lymphatic tissue injury during the reproductively active and inactive phases of Indian palm squirrels (Funambulus pennanti);
- 2010 Oct: In vitro and in vivo antitumor activity of melatonin receptor agonists;
- 2011 Jan: Extended exposure to dietary melatonin reduces tumor number and size in aged male mice;
- 2011 Jan: The melatonin action on stromal stem cells within pericryptal area in colon cancer model under constant light;
- 2011 Feb: Long-term melatonin treatment reduces ovarian mass and enhances tissue antioxidant defenses during ovulation in the rat;
- 2011 Feb: Protective effects of melatonin and octreotide against radiation-induced intestinal injury;
- 2011 Mar: Melatonin, a novel Sirt1 inhibitor, imparts antiproliferative effects against prostate cancer in vitro in culture and in vivo in TRAMP model;
- 2011 Apr: Improvement of capecitabine antitumoral activity by melatonin in pancreatic cancer;
- 2011 Oct: Melatonin exerts by an autocrine loop antiproliferative effects in cholangiocarcinoma: its synthesis is reduced favoring cholangiocarcinoma growth;
- 2011 Nov: LNCaP Prostate Cancer Growth In Vivo: Oncostatic Effects of Melatonin as Compared to Hypoxia and Reoxygenation;
- 2011 Nov-Dec: Beneficial effect of melatonin treatment on inflammation, apoptosis and oxidative stress on pancreas of a senescence accelerated mice model;
- 2012 Jan: Experimental data about melatonin effects on platelet count and functional activity;
- 2012 Jul: Glia-pinealocyte network: the paracrine modulation of melatonin synthesis by tumor necrosis factor (TNF);
- 2012 Aug: Protective effect of melatonin against radiation induced nephrotoxicity in rats;
- 2012 Oct: Melatonin attenuates gentamicin-induced nephrotoxicity and oxidative stress in rats;
- 2012 Oct-Nov: Melatonin may play a role in modulation of bax and bcl-2 expression levels to protect rat peripheral blood lymphocytes from gamma irradiation-induced apoptosis;
- 2012 Dec: Role of melatonin and luzindole in rat mammary cancer;
- 2013 Jan: Melatonin suppresses cisplatin-induced nephrotoxicity via activation of Nrf-2/HO-1 pathway;
- 2013 Jan: Prostate cancer and novel ways to deliver melatonin;
- 2013 Feb: Evaluation of radio-protective effect of melatonin on whole body irradiation induced liver tissue damage;
- 2013 Feb: Melatonin reduces X-ray radiation-induced lung injury in mice by modulating oxidative stress and cytokine expression;
- 2013 Feb: Radioprotective effect of melatonin on the cervical spinal cord in irradiated rats;
- 2013 Mar: Effects of melatonin on DNA damage induced by cyclophosphamide in rats;
- 2013 Mar: Melatonin exerts differential actions on X-ray radiation-induced apoptosis in normal mice splenocytes and Jurkat leukemia cells;
- 2013 Mar: Melatonin is involved in the apoptosis and necrosis of pancreatic cancer cell line SW-1990 via modulating of Bcl-2/Bax balance;
- 2013 Apr: Melatonin suppresses tumor progression by reducing angiogenesis stimulated by HIF-1 in a mouse tumor model;
- 2013 May: Blockage of melatonin receptors impairs p53-mediated prevention of DNA damage accumulation;
- 2013 Aug: Insulin and IGF1 enhance IL-17-induced chemokine expression through a GSK3B-dependent mechanism: a new target for melatonin's anti-inflammatory action;
- 2013 Sep: Melatonin/PGC1A/UCP1 promotes tumor slimming and represses tumor progression by initiating autophagy and lipid browning;
- 2013 Oct: Melatonin inhibits cholangiocarcinoma and reduces liver injury in Opisthorchis viverrini-infected and N-nitrosodimethylamine-treated hamsters;
- 2013 Dec: Characterization of chemically induced ovarian carcinomas in an ethanol-preferring rat model: influence of long-term melatonin treatment;
- 2014 Jan: Effect of Melatonin on Tumor Growth and Angiogenesis in Xenograft Model of Breast Cancer;
- 2014 Feb: Melatonin ameliorates oxidative stress and reproductive toxicity induced by cyclophosphamide in male mice;
- 2014 Apr: Consequences of lethal-whole-body gamma radiation and possible ameliorative role of melatonin;
- 2014 Jun: Prophylactic efficacy of melatonin on cyclophosphamide-induced liver toxicity in mice;
- 2014 Aug: Antitumour activity of melatonin in a mouse model of human prostate cancer: relationship with hypoxia signalling;
- 2014 Aug: Light exposure at night disrupts host/cancer circadian regulatory dynamics: impact on the Warburg effect, lipid signaling and tumor growth prevention;
- 2014 Sep: Melatonin potentiates the anti-tumour effect of pravastatin in rat mammary gland carcinoma model;
- 2014 Oct: Melatonin Attenuates Her-2, p38 MAPK, p-AKT, and mTOR Levels in Ovarian Carcinoma of Ethanol-Preferring Rats;
- 2014 Dec: Anti-gastric cancer effect of melatonin and Bcl-2, Bax, p21 and p53 expression changes;
- 2015 Jan: Melatonin blunts the mitochondrial/NLRP3 connection and protects against radiation-induced oral mucositis;
- 2015 Feb: Melatonin attenuates the TLR4-mediated inflammatory response through MyD88- and TRIF-dependent signaling pathways in an in vivo model of ovarian cancer;
- 2015 Mar: Expression of vascular endothelial growth factor (VEGF-A) in rat mandibular salivary gland during paraneoplastic process and treatment with cyclophosphamide and melatonin;
- 2015 Mar: Melatonin uptake through glucose transporters: a new target for melatonin inhibition of cancer;
- 2015 Apr: Oral administration of melatonin modulates the expression of tumor necrosis factor-α (TNF-α) gene in irradiated rat cervical spinal cord;
- 2015 Apr: Propionibacterium acnes Augments Antitumor, Anti-Angiogenesis and Immunomodulatory Effects of Melatonin on Breast Cancer Implanted in Mice;
- 2015 Jun: Melatonin attenuates oxidative damage induced by Acrylamide in vitro and in vivo;
- 2015 Jul: Radioprotective potential of melatonin against ⁶⁰Co γ-ray-induced testicular injury in male C57BL/6 mice;
- 2015 Sep: Ceramide metabolism regulates autophagy and apoptotic cell death induced by melatonin in liver cancer cells;
- 2015 Sep: Melatonin is a potent modulator of antioxidative defense and cellular proliferation against aluminum toxicity in rats;
- 2015 Dec: Effect of Transtympanic Injection of Melatonin on Cisplatin-Induced Ototoxicity;
- 2015 Dec: Melatonin decreases the expression of inflammation and apoptosis markers in the lung of a senescence-accelerated mice model;
- 2015 Dec: Melatonin suppression of aerobic glycolysis (Warburg effect), survival signalling and metastasis in human leiomyosarcoma;
- 2016 Jan: Melatonin decreases breast cancer metastasis by modulating Rho-associated kinase protein-1 expression;
- 2016 Jan: Melatonin inhibits AP-2β/hTERT, NF-κB/COX-2 and Akt/ERK and activates caspase/Cyto C signaling to enhance the antitumor activity of berberine in lung cancer cells;
- 2016 Jan: Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activation;
- 2016 Feb: Apoptosis is triggered by melatonin in an in vivo model of ovarian carcinoma;
- 2016 Feb: Melatonin inhibits MMP-9 transactivation and renal cell carcinoma metastasis by suppressing Akt-MAPKs pathway and NF-κB DNA-binding activity;
- 2016 Jul: Melatonin's protective effect on the salivary gland against ionized radiation damage in rats;
- 2016 Aug: Effects of melatonin and gonadal androgens on cell proliferation in the pituitary of viscachas (Lagostomus maximus maximus);
- 2016 Aug: Melatonin downregulates nuclear receptor RZR/RORγ expression causing growth-inhibitory and anti-angiogenesis activity in human gastric cancer cells in vitro and in vivo;
- 2016 Aug: Melatonin Represses Metastasis in Her2-Postive Human Breast Cancer Cells by Suppressing RSK2 Expression;
- 2016 Sep: Melatonin inhibits tumorigenicity of glioblastoma stem-like cells via the AKT-EZH2-STAT3 signaling axis;
- 2016 Oct: Melatonin enhances sensitivity to fluorouracil in oesophageal squamous cell carcinoma through inhibition of Erk and Akt pathway;
- 2016 Oct: Melatonin prevents deregulation of the sphingosine kinase/sphingosine 1-phosphate signaling pathway in a mouse model of diethylnitrosamine-induced hepatocellular carcinoma;
- 2016 Oct: Quantitative proteomic profiling reveals that diverse metabolic pathways are influenced by melatonin in an in vivo model of ovarian carcinoma;
- 2016 Oct: The effects of melatonin on liver functions in arsenic-induced liver damage;
- 2016 Nov: Melatonin synergizes the chemotherapeutic effect of 5-fluorouracil in colon cancer by suppressing PI3K/AKT and NF-κB/iNOS signaling pathways;
- 2016 Dec: Effects of melatonin on repair of DNA double strand breaks caused by ionizing radiation in rat peripheral blood;
- 2017 ???: Melatonin action on oxidative stress and tumor angiogenesis in the experimental model of hepatic carcinogenesis;
- 2017 Jan: IGFBP3 and MAPK/ERK signaling mediates melatonin-induced antitumor activity in prostate cancer;
- 2017 Feb: Melatonin attenuates 60 Co γ-ray-induced hematopoietic, immunological and gastrointestinal injuries in C57BL/6 male mice;
- 2017 Mar: Expression Levels of Two DNA Repair-related Genes under 8 Gy Ionizing Radiation and 100 Mg/Kg Melatonin Delivery In Rat Peripheral Blood;
- 2017 Mar: Melatonin Reduces Angiogenesis in Serous Papillary Ovarian Carcinoma of Ethanol-Preferring Rats;
- 2017 Apr: Melatonin protects rats from radiotherapy-induced small intestine toxicity;
- 2017 Jun: Amelioration of Dalton's lymphoma-induced angiogenesis by melatonin;
- 2017 Jun: Melatonin protects against cisplatin-induced ovarian damage in mice via the MT1 receptor and antioxidant activity;
- 2017 Jun: Synergistic effect of melatonin and ghrelin in preventing cisplatin-induced ovarian damage via regulation of FOXO3a phosphorylation and binding to the p27Kip1 promoter in primordial follicles;
- 2017 Jul: Melatonin suppresses hepatocellular carcinoma progression via lncRNA-CPS1-IT-mediated HIF-1α inactivation;
- 2017 Jul: Pre-treatment with melatonin protects against cyclophosphamide-induced oxidative stress and renal damage in mice;
- 2017 Aug: Antiproliferative and Pro-Apoptotic Activity of Melatonin Analogues on Melanoma and Breast Cancer Cells;
- 2017 Oct: Impressive Suppression of Colon Cancer Growth by Triple Combination SN38/EF24/Melatonin: "Oncogenic" Versus "Onco-Suppressive" Reactive Oxygen Species;
- 2017 Oct-Dec: Modulation of Radiation-induced Base Excision Repair Pathway Gene Expression by Melatonin;
- 2017 Nov: Transdermal administration of melatonin coupled to cryopass laser treatment as noninvasive therapy for prostate cancer;
- 2018 Jan: Protective Role of Melatonin in Streptozotocin Induced Pancreatic Damages in Diabetic Wistar Rat;
- 2018 Feb: The melatonin-MT1 receptor axis modulates tumor growth in PTEN-mutated gliomas;
- 2018 Mar: Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells;
- 2018 Mar: Melatonin Inhibits Reactive Oxygen Species-Driven Proliferation, Epithelial-Mesenchymal Transition, and Vasculogenic Mimicry in Oral Cancer;
- 2018 Mar: Melatonin suppresses thyroid cancer growth and overcomes radioresistance via inhibition of p65 phosphorylation and induction of ROS;
- 2018 Apr: Combination of melatonin and rapamycin for head and neck cancer therapy: Suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation;
- 2018 Apr: Effect of melatonin on antioxidant capacity, ınflammation and apoptotic cell death in lung tissue of diabetic rats;
- 2018 Jun: Melatonin Synergizes with Sorafenib to Suppress Pancreatic Cancer via Melatonin Receptor and PDGFR-β/STAT3 Pathway;
- 2018 Aug: Melatonin and 5-fluorouracil co-suppress colon cancer stem cells by regulating cellular prion protein-Oct4 axis;
- 2018 Aug: Mitochondria Transcription Factor A: A Putative Target for the Effect of Melatonin on U87MG Malignant Glioma Cell Line;
- 2018 Aug: Responses of Transgenic Melatonin-Enriched Goats on LPS Stimulation and the Proteogenomic Profiles of Their PBMCs;
- 2018 Sep: Melatonin Inhibits the Progression of Hepatocellular Carcinoma through MicroRNA Let7i-3p Mediated RAF1 Reduction;
- 2018 Sep: Melatonin restrains angiogenic factors in triple-negative breast cancer by targeting miR-152-3p: In vivo and in vitro studies;
- 2018 Sep: Melatonin Sensitizes Hepatocellular Carcinoma Cells to Chemotherapy Through Long Non-Coding RNA RAD51-AS1-Mediated Suppression of DNA Repair;
- 2018 Oct: Melatonin-mediated downregulation of ZNF746 suppresses bladder tumorigenesis mainly through inhibiting the AKT-MMP-9 signaling pathway;
- 2018 Oct: Melatonin suppresses TLR9-triggered proinflammatory cytokine production in macrophages by inhibiting ERK1/2 and AKT activation;
- 2018 Nov: Biochemical and histopathological evaluation of the radioprotective effects of melatonin against Gamma ray-induced skin damage in rats;
- 2018 Nov: Evaluating the Expression of NOX2 and NOX4 Signaling Pathways in Rats' Lung Tissues Following Local Chest Irradiation; Modulatory Effect of Melatonin;
- 2018 Nov: Melatonin and Its Metabolites Ameliorate UVR-Induced Mitochondrial Oxidative Stress in Human MNT-1 Melanoma Cells;
- 2018 Dec: Melatonin Sensitizes Human Colorectal Cancer Cells to γ-ray Ionizing Radiation In Vitro and In Vivo;
- 2018 Dec: Radioprotective effect of melatonin on expression of Cdkn1a and Rad50 genes in rat peripheral blood;
- 2019 Jan: Inhibition of TFEB oligomerization by co-treatment of melatonin with vorinostat promotes the therapeutic sensitivity in glioblastoma and glioma stem cells;
- 2019 Jan: Melatonin Alleviates Radiation-Induced Lung Injury via Regulation of miR-30e/NLRP3 Axis;
- 2019 Jan: Melatonin reduced endometrial hyperplasia induced by estradiol in female albino rats;
- 2019 Jan: Metformin and melatonin improve histopathological outcome of NMU-induced mammary tumors in rats;
- 2019 Jan: RNA-Seq transcriptome analysis shows anti-tumor actions of melatonin in a breast cancer xenograft model;
- 2019 Feb: Evaluation of the radioprotective effects of melatonin against ionizing radiation-induced muscle tissue injury;
- 2019 Feb: Exogenous melatonin modulates carbon ion radiation-induced immune dysfunction in mice;
- 2019 Feb: Melatonin protects against methotrexate-induced memory deficit and hippocampal neurogenesis impairment in a rat model;
- 2019 Feb: Melatonin suppresses lung cancer metastasis by inhibition of epithelial-mesenchymal transition through targeting to Twist;
- 2019 Feb: Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits;
- 2019 Feb: PK-PD based optimal dose and time for orally administered supra-pharmacological dose of melatonin to prevent radiation induced mortality in mice;
- 2019 Feb: Protective effects of genistein and melatonin on mouse liver injury induced by whole-body ionising radiation;
- 2019 Mar: Melatonin maximizes the therapeutic potential of non-preconditioned MSCs in a DEN-induced rat model of HCC;
- 2019 Apr: Melatonin protects spermatogonia from the stress of chemotherapy and oxidation via eliminating reactive oxidative species;
- 2019 May: Ameliorative effects of melatonin against solid Ehrlich carcinoma progression in female mice;
- 2019 May: Histone deacetylase 9 downregulation decreases tumor growth and promotes apoptosis in non-small cell lung cancer after melatonin treatment;
- 2019 May: Melatonin enhances sorafenib-induced cytotoxicity in FLT3-ITD acute myeloid leukemia cells by redox modification;
- 2019 May: Protective Effect of Melatonin on Cisplatin-induced Ototoxicity in Rats;
- 2019 May: Treatment with melatonin and selenium attenuates docetaxel-induced apoptosis and oxidative injury in kidney and testes of mice;
- 2019 Jun: Epigenetic inhibition of the tumor suppressor ARHI by light at night-induced circadian melatonin disruption mediates STAT3-driven paclitaxel resistance in breast cancer;
- 2019 Jun: MTNR1B loss promotes chordoma recurrence by abrogating melatonin-mediated β-catenin signaling repression;
- 2019 Jun: Melatonin inhibits lung metastasis of gastric cancer in vivo;
- 2019 Jun: Mitochondrial oxidative stress-induced brain and hippocampus apoptosis decrease through modulation of caspase activity, Ca 2+ influx and inflammatory cytokine molecular pathways in the docetaxel-treated mice by melatonin and selenium treatments;
- 2019 Jun: Pharmacological, Mechanistic, and Pharmacokinetic Assessment of Novel Melatonin-Tamoxifen Drug Conjugates as Breast Cancer Drugs;
- 2019 Jun: Role of transforming growth factor β1 in the inhibition of gastric cancer cell proliferation by melatonin in vitro and in vivo;
- 2019 Jul: Co-administering Melatonin With an Estradiol-Progesterone Menopausal Hormone Therapy Represses Mammary Cancer Development in a Mouse Model of HER2-Positive Breast Cancer;
- 2019 Jul: Melatonin Enhances the Usefulness of Ionizing Radiation: Involving the Regulation of Different Steps of the Angiogenic Process;
- 2019 Jul: Mitigation of Radiation-Induced Lung Pneumonitis and Fibrosis Using Metformin and Melatonin: A Histopathological Study;
- 2019 Jul: Protection from radiation-induced damage in rat's ileum and colon by combined regimens of melatonin and metformin: A histopathological study;
- 2019 Aug: Dietary melatonin attenuates chromium-induced lung injury via activating the Sirt1/Pgc-1α/Nrf2 pathway;
- 2019 Aug: Histopathological and Functional Evaluation of Radiation-Induced Sciatic Nerve Damage: Melatonin as Radioprotector;
- 2019 Aug: Melatonin may prevent or reverse polycystic ovary syndrome in rats;
- 2019 Aug: Melatonin promotes neuroblastoma cell differentiation by activating hyaluronan synthase 3-induced mitophagy;
- 2019 Aug: Melatonin protects mouse oocytes from DNA damage by enhancing nonhomologous end-joining repair;
- 2019 Aug: The Radioprotective Effect of Combination of Melatonin and Metformin on Rat Duodenum Damage Induced by Ionizing Radiation: A Histological Study;
- 2019 Nov: A ketogenic diet combined with melatonin overcomes cisplatin and vincristine drug resistance in breast carcinoma syngraft;
- 2019 Nov: Melatonin activates cell death programs for the suppression of uterine leiomyoma cell proliferation;
- 2019 Nov: Melatonin protects against Epirubicin-induced ovarian damage;
- 2019 Nov: The Therapeutic Effect of Melatonin on GC by Inducing Cell Apoptosis and Autophagy Induced by Endoplasmic Reticulum Stress;
- 2019 Dec: Effect of melatonin on T/B cell activation and immune regulation in pinealectomy mice;
- 2019 Jan: Melatonin Attenuates Upregulation of Duox1 and Duox2 and Protects against Lung Injury following Chest Irradiation in Rats;
- 2019 Dec: Melatonin modifies tumor hypoxia and metabolism by inhibiting HIF-1α and energy metabolic pathway in the in vitro and in vivo models of breast cancer;
- 2019 Dec: Melatonin Regulates Breast Cancer Progression by the lnc010561/miR-30/FKBP3 Axis;
- 2019 Dec: Study of the possible synergistic protective effects of Melatonin and Pregabalin in Vincristine induced peripheral neuropathy Wistar Albino rats;
- 2020 Jan: Effects of miR-34b/miR-892a Upregulation and Inhibition of ABCB1/ABCB4 on Melatonin-Induced Apoptosis in VCR-Resistant Oral Cancer Cells;
- 2020 Feb: Anti-genotoxic and anti-mutagenic effects of melatonin supplementation in a mouse model of melanoma;
- 2020 Feb: Melatonin alleviates progression of uterine endometrial cancer by suppressing estrogen/ubiquitin C/SDHB-mediated succinate accumulation;
- 2020 Feb: Melatonin attenuates doxorubicin-induced cardiotoxicity through preservation of YAP expression;
- 2020 Feb: The effects of daylight exposure on melatonin levels, Kiss1 expression, and melanoma formation in mice;
- 2020 Mar: Melatonin reverses nasopharyngeal carcinoma cisplatin chemoresistance by inhibiting the Wnt/β-catenin signaling pathway;
- 2020 Mar: Usefulness of melatonin as complementary to chemotherapeutic agents at different stages of the angiogenic process;
- 2020 May: Melatonin-triggered Post-Transcriptional and Post-Translational Modifications of ADAMTS1 Coordinately Retard Tumorigenesis and Metastasis of Renal Cell Carcinoma;
- 2020 May: Pineal gland protects against chemically induced oral carcinogenesis and inhibits tumor progression in rats;
- 2020 Jun: Melatonin Act as an Antidepressant via Attenuation of Neuroinflammation by Targeting Sirt1/Nrf2/HO-1 Signaling;
- 2020 Jun: Melatonin and Selenium Suppress Docetaxel-Induced TRPV1 Activation, Neuropathic Pain and Oxidative Neurotoxicity in Mice;
- 2020 Jun: The Effect of Zinc and Melatonin Administration on Lipid Peroxidation, IL-6 Levels, and Element Metabolism in DMBA-Induced Breast Cancer in Rats;
- 2020 Jul: Delta Tocotrienol and Melatonin in Management of Mast Cell Canine Tumor;
- 2020 Jul: Jagged2 progressively increased expression from Stage I to III of Bladder Cancer and Melatonin-mediated downregulation of Notch/Jagged2 suppresses the Bladder Tumorigenesis via inhibiting PI3K/AKT/mTOR/MMPs signaling;
- 2020 Jul: Melatonin Protects Against Apoptosis of Megakaryocytic Cells via Its Receptors and the AKT/mitochondrial/caspase Pathway;
- 2020 Aug: Melatonin restores neutrophil functions and prevents apoptosis amid dysfunctional glutathione redox system;
- 2020 Aug: Melatonin suppresses chronic restraint stress-mediated metastasis of epithelial ovarian cancer via NE/AKT/β-catenin/SLUG axis;
- 2020 Sep: Effect of concomitant treatment of curcumin and melatonin on cisplatin-induced nephrotoxicity in rats;
- 2020 Sep: Melatonin Administered before or after a Cytotoxic Drug Increases Mammary Cancer Stabilization Rates in HER2/Neu Mice;
- 2020 Sep: Zinc and melatonin supplementation ameliorates brain cortex tissue damage in DMBA-induced breast cancer in rats;
- 2020 Oct: Effects of melatonin on uterine hypertrophy/hyperplasia: A preliminary experimental rat study;
- 2020 Oct: Melatonin inhibits growth of B16 melanoma in C57BL/6 mice;
- 2020 Oct: Melatonin provides protection against cisplatin-induced ovarian damage and loss of fertility in mice;
- 2020 Nov: Melatonin derivatives combat with inflammation-related cancer by targeting the Main Culprit STAT3;
- 2020 Nov: Melatonin impedes prostate cancer metastasis by suppressing MMP-13 expression;
- 2020 Dec: Melatonin Inhibits the Progression of Oral Squamous Cell Carcinoma via Inducing miR-25-5p Expression by Directly Targeting NEDD9;
- 2020 Dec: Melatonin prevents doxorubicin-induced cardiotoxicity through suppression of AMPKα2-dependent mitochondrial damage;
- 2021 Jan: Melatonin inhibits proliferation and viability and promotes apoptosis in colorectal cancer cells via upregulation of the microRNA-34a/449a cluster;
- 2021 Jan: Melatonin interrupts osteoclast functioning and suppresses tumor-secreted RANKL expression: implications for bone metastases;
- 2021 Jan: Radioprotective effect of melatonin against radiotherapy-induced cerebral cortex and cerebellum damage in rat;
- 2021 Mar: FGF19/FGFR4 signaling axis confines and switches the role of melatonin in head and neck cancer metastasis;
- 2021 Mar: Melatonin decreases metastasis, primary tumor growth and angiogenesis in a mice model of breast cancer;
- 2021 Mar: Melatonin protects rats testes against bleomycin, etoposide, and cisplatin-induced toxicity via mitigating nitro-oxidative stress and apoptosis;
- 2021 Mar-Apr: The role of melatonin in preventing radiation-induced intestinal injury;
- 2021 May: Melatonin: A regulator of the interplay between FoxO1, miR96, and miR215 signaling to diminish the growth, survival, and metastasis of murine adenocarcinoma;
- 2021 May: Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer;
- 2021 Jun: Dietary Melatonin and Glycine Decrease Tumor Growth through Antiangiogenic Activity in Experimental Colorectal Liver Metastasis;
- 2021 Jun: Dietary Melatonin and Omega-3 Fatty Acids Induce Human Cancer Xenograft Regression In Vivo in Rats by Suppressing Linoleic Acid Uptake and Metabolism;
- 2021 Jun: Induction of EnR stress by Melatonin enhances the cytotoxic effect of Lapatinib in HER2-positive breast cancer;
- 2021 Jun: Melatonin inhibits lipid accumulation to repress prostate cancer progression by mediating the epigenetic modification of CES1;
- 2021 Jul: Melatonin inhibits lung cancer development by reversing the Warburg effect via stimulating the SIRT3/PDH axis;
- 2021 Jul: Melatonin inhibits triple-negative breast cancer progression through the Lnc049808-FUNDC1 pathway;
- 2021 Aug: Cardioprotective effects of melatonin and metformin against doxorubicin-induced cardiotoxicity in rats are through preserving mitochondrial function and dynamics;
- 2021 Aug: Combination of Melatonin and Zoledronic Acid Suppressed the Giant Cell Tumor of Bone in vitro and in vivo;
- 2021 Aug: Melatonin and hyperbaric oxygen therapies suppress colorectal carcinogenesis through pleiotropic effects and multifaceted mechanisms;
- 2021 Aug: Modulation of Radiation-Induced NADPH Oxidases in Rat's Heart Tissues by Melatonin;
- 2021 Sep: Melatonin enhances radiofrequency-induced NK antitumor immunity, causing cancer metabolism reprogramming and inhibition of multiple pulmonary tumor development;
- 2021 Sep: Melatonin inhibits proliferation, migration, and invasion by inducing ROS-mediated apoptosis via suppression of the PI3K/Akt/mTOR signaling pathway in gallbladder cancer cells;
- 2021 Sep: Melatonin potentiates the cytotoxic effect of Neratinib in HER2 + breast cancer through promoting endocytosis and lysosomal degradation of HER2;
- 2021 Sep: Melatonin reduces proliferation and promotes apoptosis of bladder cancer cells by suppressing O-GlcNAcylation of cyclin-dependent-like kinase 5;
- 2021 Sep: The Effects of Melatonin Administration on Intestinal Injury Caused by Abdominal Irradiation from Mice;
- 2021 Oct: Melatonin modulates metabolic remodeling in HNSCC by suppressing MTHFD1L-formate axis;
- 2021 Nov: Activity of Melatonin Against Gastric Cancer Growth in a Chick Embryo Tumor Xenograft Model;
- 2021 Dec: Melatonin induces apoptotic cell death through Bim stabilization by Sp1-mediated OTUD1 upregulation;
- 2022 Jan: Melatonin decreases androgen-sensitive prostate cancer growth by suppressing SENP1 expression;
- 2022 Mar: Effects of melatonin and metformin in preventing lysosome-induced autophagy and oxidative stress in rat models of carcinogenesis and the impact of high-fat diet;
- 2022 Mar: Melatonin Attenuates Dasatinib-Aggravated Hypoxic Pulmonary Hypertension via Inhibiting Pulmonary Vascular Remodeling;
- 2022 Apr: Melatonin promotes apoptosis of thyroid cancer cells via regulating the signaling of microRNA-21 (miR-21) and microRNA-30e (miR-30e);
- 2022 Nov: Development of in vitro and in vivo tools to evaluate the antiangiogenic potential of melatonin to neutralize the angiogenic effects of VEGF and breast cancer cells: CAM assay and 3D endothelial cell spheroids;
- 2022 Nov: The ubiquitin-specific protease 8 antagonizes melatonin-induced endocytic degradation of MT1 receptor to promote lung adenocarcinoma growth.
Review
- 1974 Jun: The pineal gland: a neurochemical transducer;
- 1978 Oct: Role of pineal gland in aetiology and treatment of breast cancer;
- 1979 ???: Clinical importance of melatonin;
- 1991 Oct: Melatonin: That Ubiquitously Acting Pineal Hormone;
- 1992 Feb-Mar: Breast cancer, blindness and melatonin;
- 1993 Jan: The immunoneuroendocrine role of melatonin;
- 1993 Aug: Clinical aspects of the melatonin action: impact of development, aging, and puberty, involvement of melatonin in psychiatric disease and importance of neuroimmunoendocrine interactions;
- 1993 Oct: Melatonin and human puberty: current perspectives;
- 1994 Feb: Melatonin receptors: localization, molecular pharmacology and physiological significance;
- 1995 Oct: The clinical neuroimmunotherapeutic role of melatonin in oncology;
- 1997 Jan: Melatonin in humans 1997;
- 1997 May: The validity of melatonin as an oncostatic agent;
- 1997 Jun: Melatonin in osteosarcoma: an effective drug?;
- 1997 Oct: Significance of melatonin in malignant diseases;
- 1998 Jan-Feb: Melatonin involvement in immunity and cancer;
- 1998 Mar: Melatonin: receptor-mediated events that may affect breast and other steroid hormone-dependent cancers;
- 1998 Mar: Melatonin receptor genes;
- 1998 Jul: Cellular mechanisms of melatonin action;
- 1998 Nov: Suppression of oxygen toxicity by melatonin;
- 1999 ???: Melatonin modulation of prolactin and gonadotrophin secretion. Systems ancient and modern;
- 1999 ???: Melatonin synergizes with retinoic acid in the prevention and regression of breast cancer;
- 1999 Jan: Melatonin in dermatology. Experimental and clinical aspects;
- 2000 Apr: Melatonin and mammary pathological growth;
- 2000 Apr: Melatonin, experimental basis for a possible application in breast cancer prevention and treatment;
- 2001 Mar: Melatonin, mitochondria, and cellular bioenergetics;
- 2002 Feb: Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy;
- 2002 Mar: Is there a role for melatonin in supportive care?;
- 2002 Apr: Future of melatonin as a therapeutic agent;
- 2002 May: Melatonin: from basic research to cancer treatment clinics;
- 2002 Jul: Melatonin and breast cancer (Melatonina y cáncer de mama) - (Only Spanish Language);
- 2002 Sep: Melatonin protects against oxidative stress caused by delta-aminolevulinic acid: implications for cancer reduction;
- 2002 Oct: Gastrointestinal melatonin: localization, function, and clinical relevance;
- 2002 Oct: Melatonin: reducing the toxicity and increasing the efficacy of drugs;
- 2003 Jun: Melatonin and mammary cancer: a short review;
- 2003 Jul: Melatonin and cell death: differential actions on apoptosis in normal and cancer cells;
- 2003 Oct: Melatonin as an antioxidant: biochemical mechanisms and pathophysiological implications in humans;
- 2004 Mar: Physiological and metabolic functions of melatonin;
- 2004 Jul: Melatonin as a radioprotective agent: a review;
- 2005 Mar: Melatonin as an organoprotector in the stomach and the pancreas;
- 2005 May: Melatonin-estrogen interactions in breast cancer;
- 2005 Jul: A review of the multiple actions of melatonin on the immune system;
- 2005 Jul: On the role of melatonin in skin physiology and pathology;
- 2005 Jul-Aug: The therapeutic application of melatonin in supportive care and palliative medicine;
- 2005 Sep: A proposed mechanism to explain the stimulatory effect of melatonin on antioxidative enzymes;
- 2005 Nov: Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis;
- 2005 Dec: Melatonin in Protection against Oxidative Damage Caused by Potential Carcinogens;
- 2006 ???: Melatonin, The Hormone of Darkness: A Ray of Hope For Many Diseases;
- 2006 Mar: Estrogen-signaling pathway: a link between breast cancer and melatonin oncostatic actions;
- 2006 Apr: MELATONIN: POTENTIAL UTILITY FOR IMPROVING PUBLIC HEALTH;
- 2006 Apr: The role of melatonin in immuno-enhancement: potential application in cancer;
- 2006 Oct: Melatonin in cancer management: progress and promise;
- 2006 May-Jun: Melatonin as antioxidant, geroprotector and anticarcinogen;
- 2006 Nov: Melatonin in humans 2006;
- 2006 Nov: Therapeutic treatments potentially mediated by melatonin receptors: potential clinical uses in the prevention of osteoporosis, cancer and as an adjuvant therapy;
- 2006 Dec: Melatonin in pathogenesis and therapy of cancer;
- 2007 Jan: Melatonin role in the mitochondrial function;
- 2007 Jan: Radio Protective Effect of Melatonin: MINIREVIEW;
- 2007 Jun: Melatonin: potential functions in the oral cavity;
- 2007 Jul: A radiobiological review on melatonin: a novel radioprotector;
- 2007 Aug: Melatonin and its role in oxidative stress related diseases of oral cavity;
- 2007 Aug: Towards rational and evidence-based use of melatonin in prostate cancer prevention and treatment;
- 2007 Dec: Melatonin and its influence on immune system;
- 2008 Jan: Epigenetic regulation: a new research area for melatonin?;
- 2008 Apr: Physiological Effects of Melatonin: Role of Melatonin Receptors and Signal Transduction Pathways;
- 2008 May: Melatonin: adjuvant therapy of malignant tumors;
- 2008 May: Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new?;
- 2008 Sep: Melatonin and the ovary: physiological and pathophysiological implications;
- 2008 Sep: Melatonin as a major skin protectant: from free radical scavenging to DNA damage repair;
- 2008 Sep: Melatonin combats molecular terrorism at the mitochondrial level;
- 2008 Sep: Therapeutic actions of melatonin in cancer: possible mechanisms;
- 2008 Oct: Melatonin: fifty years of scientific journey from the discovery in bovine pineal gland to delineation of functions in human;
- 2008 Nov: Clinical aspects of melatonin;
- 2008 Dec: Melatonin as a selective estrogen enzyme modulator;
- 2009 Jan-Feb: Melatonin: an established antioxidant worthy of use in clinical trials;
- 2009 Feb: Melatonin and breast cancer: cellular mechanisms, clinical studies and future perspectives;
- 2009 May: Role of melatonin in the epigenetic regulation of breast cancer;
- 2009 Jun: Melatonin modulates microfilament phenotypes in epithelial cells: implications for adhesion and inhibition of cancer cell migration;
- 2009 Aug: Circulating melatonin and the risk of breast and endometrial cancer in women;
- 2009 Sep: MT1 melatonin receptors and their role in the oncostatic action of melatonin;
- 2009 Dec: Nutrition and orthomolecular supplementation in lung cancer patients;
- 2010 ???: Protective effects of melatonin against oxidative damage of macromolecules caused by selected potential carcinogens;
- 2010 Jan: Melatonin maintains adult hippocampal neurogenesis and cognitive functions after irradiation;
- 2010 Jan: Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer;
- 2010 Apr: Melatonin in diseases of the oral cavity;
- 2010 May: Melatonin: a multitasking molecule;
- 2010 Jun: Effects of Melatonin: Basics Studies and Clinical Applications;
- 2010 Jul: Clinical uses of melatonin: evaluation of human trials;
- 2010 Sep: International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors;
- 2010 Oct: Melatonin signaling and cell protection function;
- 2010 Nov: Melatonin: action as antioxidant and potential applications in human disease and aging;
- 2010 Nov-Dec: Melatonin: cell death modulator;
- 2010 Dec: Basic mechanisms involved in the anti-cancer effects of melatonin;
- 2010 Dec: Melatonin: Helping cells cope with oxidative disaster;
- 2011 Mar: Melatonin--a pleiotropic, orchestrating regulator molecule;
- 2011 Apr: Drug-mediated ototoxicity and tinnitus: alleviation with melatonin;
- 2011 May: Melatonin, immune function and cancer;
- 2011 May: Melatonin in mitochondrial dysfunction and related disorders;
- 2011 Jun: The photoperiod, circadian regulation and chronodisruption: the requisite interplay between the suprachiasmatic nuclei and the pineal and gut melatonin;
- 2011 Aug: New paradigms in chronic intestinal inflammation and colon cancer: role of melatonin;
- 2011 Sep: Melatonin and associated signaling pathways that control normal breast epithelium and breast cancer;
- 2011 Sep: Melatonin and cancer: current knowledge and its application to oral cavity tumours;
- 2011 Oct: A new perspective in Oral health: potential importance and actions of melatonin receptors MT1, MT2, MT3, and RZR/ROR in the oral cavity;
- 2011 Oct: Circadian regulation of molecular, dietary, and metabolic signaling mechanisms of human breast cancer growth by the nocturnal melatonin signal and the consequences of its disruption by light at night;
- 2011 Dec: Melatonin protection from chronic, low-level ionizing radiation;
- 2012 Jan: Melatonin membrane receptors in peripheral tissues: distribution and functions;
- 2012 Jan: Neurobiology, pathophysiology, and treatment of melatonin deficiency and dysfunction;
- 2012 Apr: New perspectives in melatonin uses;
- 2012 May: Breast cancer therapy based on melatonin;
- 2012 May: Melatonin: a novel indolamine in oral health and disease;
- 2012 May: The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials;
- 2012 Jun: Melatonin uses in oncology: breast cancer prevention and reduction of the side effects of chemotherapy and radiation;
- 2012 Jul: Role of melatonin in cancer treatment;
- 2012 Aug: Melatonin, a natural programmed cell death inducer in cancer;
- 2012 Dec: Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials;
- 2012 Dec: Oxidative damage to macromolecules in the thyroid - experimental evidence;
- 2013 Jan: A review of the molecular aspects of melatonin's anti-inflammatory actions: recent insights and new perspectives;
- 2013 Jan: Melatonin Anticancer Effects: Review (Di Bella's Foundation);
- 2013 Jan: Therapeutic actions of melatonin on gastrointestinal cancer development and progression;
- 2013 Feb: Age-related decline in melatonin and its MT1 receptor are associated with decreased sensitivity to melatonin and enhanced mammary tumor growth;
- 2013 Feb: Melatonin and synthetic analogs as antioxidants;
- 2013 Feb: Therapeutic applications of melatonin;
- 2013 Mar: Mechanisms involved in the pro-apoptotic effect of melatonin in cancer cells;
- 2013 Apr: Melatonin: buffering the immune system;
- 2013 Jun: Molecular mechanisms of melatonin's inhibitory actions on breast cancers;
- 2013 Sep: A molecular and chemical perspective in defining melatonin receptor subtype selectivity;
- 2013 Sep: The role of melatonin in the cells of the innate immunity: a review;
- 2013 Oct: Update on the role of melatonin in the prevention of cancer tumorigenesis and in the management of cancer correlates, such as sleep-wake and mood disturbances: review and remarks;
- 2013 Nov: Role of Melatonin and Melatonin Receptors in Pharmacology and Pharmacotherapy of Cancer;
- 2013 Dec: Molecular mechanisms of the pro-apoptotic actions of melatonin in cancer: a review;
- 2013 Dec: Sleep duration and cancer risk: a systematic review and meta-analysis of prospective studies;
- 2014 Jan: Action of melatonin on squamous cell carcinoma and other tumors of the oral cavity (Review);
- 2014 Jan: Cytochromes p450 and skin cancer: role of local endocrine pathways;
- 2014 Jan: Melatonin and Aromatase in Breast Cancer;
- 2014 Feb: Melatonin regulation of biliary functions;
- 2014 Apr: MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential;
- 2014 Apr: Melatonin regulates mesenchymal stem cell differentiation: a review;
- 2014 Apr: Protective effects of melatonin in reducing oxidative stress and in preserving the fluidity of biological membranes: a review;
- 2014 Apr-Jun: Potential role of melatonin in prevention and treatment of oral carcinoma;
- 2014 May: A review of metal-catalyzed molecular damage: protection by melatonin;
- 2014 May: Can Melatonin Help Us in Radiation Oncology Treatments?;
- 2014 May: Melatonin modulation of crosstalk among malignant epithelial, endothelial and adipose cells in breast cancer (Review);
- 2014 Jun: Understanding melatonin receptor pharmacology: latest insights from mouse models, and their relevance to human disease;
- 2014 Jul: Expression and putative functions of melatonin receptors in malignant cells and tissues;
- 2014 Jul: Urinary excretion of melatonin and association with breast cancer: meta-analysis and review of the literature;
- 2014 Aug: Extrapineal melatonin: sources, regulation, and potential functions;
- 2014 Aug: Melatonin's protective effect against UV radiation: a systematic review of clinical and experimental studies;
- 2014 Aug: The physiological effectiveness on Melatonin - (Only Lithuanian Language - Abstract in English);
- 2014 Aug: The Potential Use of Melatonin for Preventing Cisplatin Ototoxicity: An Insight for a Clinical Approach;
- 2014 Sep: Melatonin and cancer;
- 2014 Sep: Melatonin avoids anatomofunctional changes associated to aging in a Rat model;
- 2014 Sep: Melatonin: Exceeding Expectations;
- 2014 Oct: Melatonin as a proteasome inhibitor. Is there any clinical evidence?;
- 2014 Nov: Melatonin Receptors and Their Preventive Role in Carcinogenesis;
- 2014 Dec: Protecting the melatonin rhythm through circadian healthy light exposure;
- 2015 ???: Melatonin, its metabolites and its synthetic analogs as multi-faceted compounds: antioxidant, prooxidant and inhibitor of bioactivation reactions;
- 2015 Feb: Melatonin in the oral cavity: physiological and pathological implications;
- 2015 Mar: Drug Targets for Cancer Treatment: An Overview;
- 2015 Mar: Melatonin as a treatment for gastrointestinal cancer: a review;
- 2015 Apr: Melatonin: an inhibitor of breast cancer;
- 2015 Apr: Pharmacological aspects of melatonin in regulating various physiological functions: a review;
- 2015 May: Prooxidant effects of melatonin: a brief review;
- 2015 May: The influence of melatonin on the immune system and cancer;
- 2015 Jun: Melatonin as a stabilizer of mitochondrial function: role in diseases and aging;
- 2015 Jul: Circadian disruption and breast cancer: An epigenetic link?;
- 2015 Jul: Melatonin: a potential intervention for hepatic steatosis;
- 2015 Jul: Evaluating the Oxidative Stress in Inflammation: Role of Melatonin;
- 2015 Jul: Melatonin and endoplasmic reticulum stress: relation to autophagy and apoptosis;
- 2015 Aug: Anticancer Effects and uses of Melatonin: A Review;
- 2015 Aug: Clinical pharmacokinetics of melatonin: a systematic review;
- 2015 Aug: Molecular aspects of melatonin (MLT)-mediated therapeutic effects;
- 2015 Sep: Melatonin: an ancient molecule that makes oxygen metabolically tolerable;
- 2015 Sep: Glioma: Tryptophan Catabolite and Melatoninergic Pathways Link microRNA, 14-3- 3, Chromosome 4q35, Epigenetic Processes and other Glioma Biochemical Changes;
- 2015 Oct: Melatonin as a Potent and Inducible Endogenous Antioxidant: Synthesis and Metabolism;
- 2015 Oct: MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective;
- 2016 Jan: Melatonin as Protection Against Radiation Injury: A Systematic Review;
- 2016 Jan: Melatonin in complex treatment for colorectal cancer patients;
- 2016 Jan: Melatonin-Induced Oncostasis, Mechanisms and Clinical Relevance;
- 2016 Mar: Melatonin, an inhibitory agent in breast cancer;
- 2016 Mar: Oncostatic-Cytoprotective Effect of Melatonin and Other Bioactive Molecules: A Common Target in Mitochondrial Respiration;
- 2016 Apr: COP1 and COP9 signalosome, evolutionarily conserved photomorphogenic proteins as possible targets of melatonin;
- 2016 Apr: Circadian Dysrhythmias, Physiological Aberrations, and the Link to Skin Cancer;
- 2016 Apr: Melatonin as a potential anticarcinogen for non-small-cell lung cancer;
- 2016 May: Inflammaging, Metabolic Syndrome and Melatonin: A Call for Treatment Studies;
- 2016 May: Role of Melatonin in the Pathophysiology of Cancer;
- 2016 Jun: A Review of Melatonin, Its Receptors and Drugs;
- 2016 Jul: Therapeutic potential of melatonin in oral medicine and periodontology;
- 2016 Aug: Melatonin and Respiratory Diseases: A Review;
- 2016 Oct: Cancer metastasis: mechanisms of inhibition by melatonin;
- 2016 Nov: Cancer and Aging: Why Bother about Light at Night?;
- 2016 Dec: Melatonin: A Mitochondrial Targeting Molecule Involving Mitochondrial Protection and Dynamics;
- 2016 Dec: Melatonin as a promising agent of regulating stem cell biology and its application in disease therapy;
- 2016 Dec: Melatonin's role as a co-adjuvant treatment in colonic diseases: A review;
- 2016 Dec: Chapter 19 - The Pineal Gland and Melatonin;
- 2017 Jan: Melatonin and human mitochondrial diseases;
- 2017 Feb: Melatonin and sirtuins: A "not-so unexpected" relationship;
- 2017 Mar: Inhibitory effects of melatonin on breast cancer - (Only Chinese Language - Abstract in English);
- 2017 Mar: Melatonin signaling in T cells: Functions and applications;
- 2017 Apr: Melatonin: Pharmacology, Functions and Therapeutic Benefits;
- 2017 Apr: Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis;
- 2017 Apr: The melatonin immunomodulatory actions in radiotherapy;
- 2017 May: Effects of Melatonin and Its Analogues on Pancreatic Inflammation, Enzyme Secretion, and Tumorigenesis;
- 2017 May: Oral Mucositis: Melatonin Gel an Effective New Treatment;
- 2017 Aug: Melatonin as an anti-inflammatory agent in radiotherapy;
- 2017 Aug: Molecular Interactions of Autophagy with the Immune System and Cancer;
- 2017 Sep: Melatonin and Hippo Pathway: Is There Existing Cross-Talk?;
- 2017 Sep: Melatonin as a multifunctional anti-cancer molecule: Implications in gastric cancer;
- 2017 Sep: Melatonin: does it have utility in the treatment of haematological neoplasms?;
- 2017 Oct: Melatonin as an Anti-Inflammatory Agent Modulating Inflammasome Activation;
- 2017 Nov: A Review on Melatonin’s Effects in Cancer: Potential Mechanisms;
- 2017 Nov: Effects of melatonin supplementation on blood lipid concentrations: A systematic review and meta-analysis of randomized controlled trials;
- 2017 Nov: Melatonin, mitochondria, and the cancer cell;
- 2017 Dec: Melatonin with adenosine solubilized in water and stabilized with glycine for oncological treatment - technical preparation, effectivity and clinical findings;
- 2018 Jan: Melatonin bioengineered: A New Possible Strategy for Treatment of Breast Cancer;
- 2018 Feb: Effects of melatonin regulating on growth and development of hard tissues - (Only Chinese Language - Abstract in English);
- 2018 Feb: Melatonin and breast cancer: Evidences from preclinical and human studies;
- 2018 Feb: Melatonin and Cancer Hallmarks;
- 2018 Feb: Melatonin: A Molecule for Reducing Breast Cancer Risk;
- 2018 Mar: Does the use of melatonin overcome drug resistance in cancer chemotherapy?;
- 2018 Mar: Therapeutic potential of melatonin for breast cancer radiation therapy patients;
- 2018 May: The Role of Melatonin in Cancer Development;
- 2018 Jul: Mechanisms Underlying Tumor Suppressive Properties of Melatonin;
- 2018 Jul: Phytomelatonin versus synthetic melatonin in cancer treatments;
- 2018 Aug: Melatonin as an adjuvant in radiotherapy for radioprotection and radiosensitization;
- 2018 Aug: Melatonin Mitigates Mitochondrial Meltdown: Interactions with SIRT3;
- 2018 Aug: Preventive measures in oral cancer: An overview;
- 2018 Aug: The protective role of melatonin in chemotherapy-induced nephrotoxicity: a review of non-clinical studies;
- 2018 Aug: The role of melatonin, a multitasking molecule, in retarding the processes of ageing;
- 2018 Sep: Adjuvant chemotherapy with melatonin for targeting human cancers: A review;
- 2018 Sep: Melatonin and cancer: From the promotion of genomic stability to use in cancer treatment;
- 2018 Sep: Melatonin and pancreatic cancer: Current knowledge and future perspectives;
- 2018 Oct: Melatonin: An Anti-Tumor Agent in Hormone-Dependent Cancers;
- 2018 Oct: Promising Antineoplastic Actions of Melatonin;
- 2018 Oct: Therapeutic potential of melatonin related to its role as an autophagy regulator: A review;
- 2018 Nov: Melatonin, a toll-like receptor inhibitor: Current status and future perspectives;
- 2018 Nov: Melatonin and Its Indisputable Effects on the Health State;
- 2018 Nov: Therapeutic strategies of melatonin in cancer patients: a systematic review and meta-analysis;
- 2018 Dec: Melatonin May Increase Anticancer Potential of Pleiotropic Drugs;
- 2019 Jan: Melatonin and its anti-glioma functions: a comprehensive review;
- 2019 Jan: Melatonin in macrophage biology: Current understanding and future perspectives;
- 2019 Jan: Potential use of melatonin in skin cancer treatment: A review of current biological evidence;
- 2019 Feb: Melatonin and oral squamous cell carcinoma: current knowledge and future perspectives;
- 2019 Feb: Mitochondria: the birth place, battle ground and the site of melatonin metabolism in cells;
- 2019 Mar: Melatonin is a potential inhibitor of ovarian cancer: molecular aspects;
- 2019 Mar: Melatonin-mediated regulation of autophagy: Making sense of double-edged sword in cancer;
- 2019 Mar: Melatonin, pineal gland and sleep disorders: from theory to practice;
- 2019 Mar: Mitochondrial functions and melatonin: a tour of the reproductive cancers;
- 2019 Apr: Melatonin is an appropriate candidate for breast cancer treatment: Based on known molecular mechanisms;
- 2019 Apr: The emergence of melatonin in oncology: Focus on colorectal cancer;
- 2019 Apr: The potential utility of melatonin in the treatment of childhood cancer;
- 2019 May: Melatonin: A new inhibitor agent for cervical cancer treatment;
- 2019 May: Melatonin and non-small cell lung cancer: new insights into signaling pathways;
- 2019 May: Modulation of apoptosis by melatonin for improving cancer treatment efficiency: An updated review;
- 2019 May: The potential therapeutic actions of melatonin in colorectal cancer;
- 2019 Jun: Clinical uses of melatonin: evaluation of human trials on cancer treatment;
- 2019 Jun: Clock genes and the role of melatonin in cancer cells: an overview;
- 2019 Jun: Glioblastoma: Role of Mitochondria N-acetylserotonin/Melatonin Ratio in Mediating Effects of miR-451 and Aryl Hydrocarbon Receptor and in Coordinating Wider Biochemical Changes;
- 2019 Jun: Neuroendocrine Aspects of Skin Aging;
- 2019 Jun: Repercussions of melatonin on the risk of breast cancer: a systematic review and meta-analysis;
- 2019 Jul: Breast cancer: Occluded role of mitochondria N-acetylserotonin/melatonin ratio in co-ordinating pathophysiology;
- 2019 Jul: Clinical Applications of Melatonin in Radiotherapy: a Review;
- 2019 Jul: Immunoregulatory role of melatonin in cancer;
- 2019 Jul: Melatonin: An important anticancer agent in colorectal cancer;
- 2019 Jul: Melatonin as a potential modulator of Nrf2;
- 2019 Aug: Inhibition of mitochondrial pyruvate dehydrogenase kinase: a proposed mechanism by which melatonin causes cancer cells to overcome cytosolic glycolysis, reduce tumor biomass and reverse insensitivity to chemotherapy;
- 2019 Aug: Melatonin and its ubiquitous anticancer effects;
- 2019 Aug: Melatonin as a potential inhibitor of colorectal cancer: Molecular mechanisms;
- 2019 Aug: Understanding the role of melatonin in cancer metabolism;
- 2019 Sep: Single Cell Sequencing of the Pineal Gland: The Next Chapter;
- 2019 Sep: Therapeutic Opportunities in Colorectal Cancer: Focus on Melatonin Antioncogenic Action;
- 2019 Oct: Boosting immune system against cancer by melatonin: A mechanistic viewpoint;
- 2019 Nov: Indole-based melatonin analogues: Synthetic approaches and biological activity;
- 2019 Nov: Melatonin: A promising agent targeting leukemia;
- 2019 Nov: Melatonin: an anti-tumor agent for osteosarcoma;
- 2019 Nov: Potential of Melatonin as Adjuvant Therapy of Oral Cancer in the Era of Epigenomics;
- 2019 Dec: Molecular and Cellular Mechanisms of Melatonin in Osteosarcoma;
- 2019 Dec: THE PRO-APOPTOTIC MECHANISMS OF MELATONIN IN CANCER;
- 2019 Dec: The Role of Melatonin in Colorectal Cancer;
- 2019 Dec: The role of melatonin on doxorubicin-induced cardiotoxicity: A systematic review;
- 2020 Jan: Antioxidants and Neuron-Astrocyte Interplay in Brain Physiology: Melatonin, a Neighbor to Rely on;
- 2020 Jan: Daily and seasonal mitochondrial protection: Unraveling common possible mechanisms involving vitamin D and melatonin;
- 2020 Jan: Melatonin inhibits Warburg-dependent cancer by redirecting glucose oxidation to the mitochondria: a mechanistic hypothesis;
- 2020 Feb: Melatonin in Mitochondria: Mitigating Clear and Present Dangers;
- 2020 Mar: Melatonin's Antineoplastic Potential Against Glioblastoma;
- 2020 Mar: New insights into antimetastatic signaling pathways of melatonin in skeletomuscular sarcoma of childhood and adolescence;
- 2020 Mar: Quality of life for older patients with cancer: a review of the evidence supporting melatonin use;
- 2020 Mar: Targeting cancer stem cells by melatonin: Effective therapy for cancer treatment;
- 2020 Mar: The regulatory role of melatonin in skeletal muscle;
- 2020 Apr: Melatonin: An atypical hormone with major functions in the regulation of angiogenesis;
- 2020 May: Utilizing Melatonin to Alleviate Side Effects of Chemotherapy: A Potentially Good Partner for Treating Cancer With Ageing;
- 2020 Jun: Glioblastoma chemoresistance: roles of the mitochondrial melatonergic pathway;
- 2020 Jun: Melatonin: an endogenous miraculous indolamine, fights against cancer progression;
- 2020 Jun: Melatonin and Mesenchymal Stem Cells as a Key for Functional Integrity for Liver Cancer Treatment;
- 2020 Jun: Physiological and Pharmacological Perspectives of Melatonin;
- 2020 Jun: Role and Therapeutic Potential of Melatonin in the Central Nervous System and Cancers;
- 2020 Jul: Healthy Behaviors through Behavioral Design-Obesity Prevention;
- 2020 Jul: Melatonin as a Radio-Sensitizer in Cancer;
- 2020 Jul: Regulation of cancer cell glucose metabolism is determinant for cancer cell fate after melatonin administration;
- 2020 Jul: The role of melatonin in colorectal cancer treatment: a comprehensive review;
- 2020 Aug: Aryl Hydrocarbon Receptor Role in Co-Ordinating SARS-CoV-2 Entry and Symptomatology: Linking Cytotoxicity Changes in COVID-19 and Cancers; Modulation by Racial Discrimination Stress;
- 2020 Aug: Cellular Mechanisms of Melatonin: Insight from Neurodegenerative Diseases;
- 2020 Aug: Ionizing Radiation as a Source of Oxidative Stress-The Protective Role of Melatonin and Vitamin D;
- 2020 Aug: Melatonin and gastrointestinal cancers: Current evidence based on underlying signaling pathways;
- 2020 Sep: A meta-analysis of microRNA networks regulated by melatonin in cancer: Portrait of potential candidates for breast cancer treatment;
- 2020 Sep: Melatonin: A Potential Therapeutic Option for Breast Cancer;
- 2020 Sep: Melatonin and urological cancers: a new therapeutic approach;
- 2020 Sep: Melatonin as a potential inhibitor of kidney cancer: A survey of the molecular processes;
- 2020 Sep: The potential therapeutic effects of melatonin on breast cancer: An invasion and metastasis inhibitor;
- 2020 Sep: Two neuroendocrine G protein-coupled receptor molecules, somatostatin and melatonin: Physiology of signal transduction and therapeutic perspectives (Di Bella's Foundation);
- 2020 Nov: Is Melatonin the Cornucopia of the 21st Century?;
- 2020 Nov: Ischemic stroke, obesity, and the anti-inflammatory role of melatonin;
- 2020 Nov: Melatonin and regulation of autophagy: Mechanisms and therapeutic implications;
- 2020 Dec: Therapeutic targets of cancer drugs: Modulation by melatonin;
- 2020 Dec: Tumour Microenvironment: Roles of the Aryl Hydrocarbon Receptor, O-GlcNAcylation, Acetyl-CoA and Melatonergic Pathway in Regulating Dynamic Metabolic Interactions across Cell Types-Tumour Microenvironment and Metabolism;
- 2021 Jan: Melatonin as an Antitumor Agent against Liver Cancer: An Updated Systematic Review;
- 2021 Jan: Melatonin as an Oncostatic Molecule Based on Its Anti-Aromatase Role in Breast Cancer;
- 2021 Jan: Utilization of redox modulating small molecules that selectively act as pro-oxidants in cancer cells to open a therapeutic window for improving cancer therapy;
- 2021 Feb: Melatonin and Cancer: A Polyhedral Network Where the Source Matters;
- 2021 Mar: An updated review of mechanistic potentials of melatonin against cancer: pivotal roles in angiogenesis, apoptosis, autophagy, endoplasmic reticulum stress and oxidative stress;
- 2021 Mar: Anti-Inflammatory Activity of Melatonin: a Focus on the Role of NLRP3 Inflammasome;
- 2021 Mar: Involvement of NRF2 in Breast Cancer and Possible Therapeutical Role of Polyphenols and Melatonin;
- 2021 Mar: The inhibitory effect of melatonin on human prostate cancer;
- 2021 Mar-Apr: The Intricate Relationship between Melatonin and Breast Cancer: A Short Review;
- 2021 Apr: Melatonin as a Potential Multitherapeutic Agent;
- 2021 Apr: Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities;
- 2021 May: The melatonergic pathway and its interactions in modulating respiratory system disorders;
- 2021 Jun: A New Paradigm in the Relationship between Melatonin and Breast Cancer: Gut Microbiota Identified as a Potential Regulatory Agent;
- 2021 Jun: Exosomes and Melatonin: Where Their Destinies Intersect;
- 2021 Jun: Melatonin as an Adjuvant to Antiangiogenic Cancer Treatments;
- 2021 Jun: Melatonin and neuroblastoma: a novel therapeutic approach;
- 2021 Jun: Melatonin inhibits lipid accumulation to repress prostate cancer progression by mediating the epigenetic modification of CES1;
- 2021 Jun: The role of melatonin on radiation-induced pneumonitis and lung fibrosis: A systematic review;
- 2021 Aug: Melatonin as a promising modulator of aging related neurodegenerative disorders: Role of microRNAs;
- 2021 Sep: Melatonin-A New Prospect in Prostate and Breast Cancer Management;
- 2021 Oct: Melatonin as a Therapeutic Agent for the Inhibition of Hypoxia-Induced Tumor Progression: A Description of Possible Mechanisms Involved;
- 2021 Oct: Melatonin: A smart molecule in the DNA repair system;
- 2021 Nov: Melatonin and Pathological Cell Interactions: Mitochondrial Glucose Processing in Cancer Cells;
- 2021 Dec: Membrane Melatonin Receptors Activated Cell Signaling in Physiology and Disease;
- 2021 Dec: Usefulness of Melatonin and Other Compounds as Antioxidants and Epidrugs in the Treatment of Head and Neck Cancer;
- 2022 Jan: Antitumor and Protective Effects of Melatonin: The Potential Roles of MicroRNAs;
- 2022 Jan: Chronoradiobiology of Breast Cancer: The Time Is Now to Link Circadian Rhythm and Radiation Biology;
- 2022 Jan: Effects of exogenous melatonin supplementation on health outcomes: An umbrella review of meta-analyses based on randomized controlled trials;
- 2022 Jan: Melatonin: Regulation of Prion Protein Phase Separation in Cancer Multidrug Resistance;
- 2022 Jan: Melatonin/Cyclodextrin Inclusion Complexes: A Review;
- 2022 Jan: The interplay of pineal hormones and socioeconomic status leading to colorectal cancer disparity;
- 2022 Feb: Melatonin and the Programming of Stem Cells;
- 2022 Feb: Melatonin as the Cornerstone of Neuroimmunoendocrinology;
- 2022 Feb: The potential anti-cancer effects of melatonin on breast cancer;
- 2022 Mar: Impact of Circadian Rhythms on the Development and Clinical Management of Genitourinary Cancers;
- 2022 Mar: Use of Melatonin in Cancer Treatment: Where Are We?;
- 2022 Apr: The rationale for treating uveal melanoma with adjuvant melatonin: a review of the literature;
- 2022 May: Modulation of the immune system by melatonin; implications for cancer therapy;
- 2022 May: Oncostatic activities of melatonin: Roles in cell cycle, apoptosis, and autophagy;
- 2022 Aug: Understanding the Mechanism of Action of Melatonin, Which Induces ROS Production in Cancer Cells;
- 2022 Nov: An Exclusive Review of Melatonin Effects on Mammalian Melanocytes and Melanoma.
Commenti - Editoriali - Lettere all' Editore
- 1999 Aug: Re: a significant correlation between melatonin deficiency and endometrial cancer;
- 2004 Oct: Mechanisms of cancer inhibition by melatonin;
- 2005 Sep: Should we control the pineal status of patients following brain radiotherapy?;
- 2006 Jun: Glioma, melatonin, and radiotherapy;
- 2008 Sep: Melatonin as an adjuvant to therapeutic prostate cancer vaccines;
- 2011 May: The disaster in Japan: utility of melatonin in providing protection against ionizing radiation;
- 2013 Apr: Melatonin and its contribution to tumor attenuation in systemic malignancies;
- 2014 ???: Basic and clinical aspects of melatonin in the gastrointestinal tract. New advancements and future perspectives;
- 2015 Feb: Melatonin, sleep, and prostate cancer in elderly men: study, hypothesis development, and icelandic options;
- 2015 Oct-Dec: The profile of melatonin receptors gene expression and genes associated with their activity in colorectal cancer: a preliminary report;
- 2018 Apr: Melatonin for supportive and selective cancer therapeutics;
- 2019 Jul: Breast cancer: Occluded role of mitochondria N-acetylserotonin/melatonin ratio in co-ordinating pathophysiology;
- 2020 Mar: Injectable melatonin: an anti-cancer and anti-viral treatment option;
- 2020 May: Melatonin From an Antioxidant to a Classic Hormone or a Tissue Factor: Experimental and Clinical Aspects 2019;
- 2020 Jul: Switching Diseased Cells from Cytosolic Aerobic Glycolysis to Mitochondrial Oxidative Phosphorylation: A Metabolic Rhythm Regulated by Melatonin?;
- 2020 Jul: Understanding the Oncostatic Actions Displayed by Melatonin in Colorectal Cancer Therapy;
- 2021 Jan: Melatonin synthesis in and uptake by mitochondria: implications for diseased cells with dysfunctional mitochondria;
- 2021 Jul: Melatonin and vitamin D: complementary therapeutic strategies for breast cancer;
- 2022 Mar: Alkylating Agent-Induced Toxicity and Melatonin-Based Therapies.
Meta-analisi
- 2012 Dec: Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials;
- 2013 Dec: Sleep duration and cancer risk: a systematic review and meta-analysis of prospective studies;
- 2014 Jul: Urinary excretion of melatonin and association with breast cancer: meta-analysis and review of the literature;
- 2017 Nov: Effects of melatonin supplementation on blood lipid concentrations: A systematic review and meta-analysis of randomized controlled trials;
- 2018 Nov: Therapeutic strategies of melatonin in cancer patients: a systematic review and meta-analysis;
- 2019 Apr: Association between total sleep time and all cancer mortality: Non-linear dose-response meta-analysis of cohort studies;
- 2019 Aug: Melatonin as a potential inhibitor of colorectal cancer: Molecular mechanisms;
- 2020 Sep: A meta-analysis of microRNA networks regulated by melatonin in cancer: Portrait of potential candidates for breast cancer treatment;
- 2021 Jun: Melatonin inhibits lipid accumulation to repress prostate cancer progression by mediating the epigenetic modification of CES1
Studi preclinici
- 2009 Nov: Alteration of the MT1 melatonin receptor gene and its expression in primary human breast tumors and breast cancer cell lines;
- 2011 May: Declining melatonin levels and MT1 receptor expression in aging rats is associated with enhanced mammary tumor growth and decreased sensitivity to melatonin;
- 2013 Feb: Expression of melatonin receptors in triple negative breast cancer (TNBC) in African American and Caucasian women: relation to survival;
In Vivo (Solo uomo: Case Reports/Serie, Trials Clinici, Studi Comparativi, studi Randomizzati e Controllati, Controllati e Studi Retrospettivi)
- 1977 Oct: The effects of oral melatonin on skin color and on the release of pituitary hormones;
- 1982 May: Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer;
- 1985 Jul: Plasma melatonin and the hormone-dependency of human breast cancer;
- 1985 Aug: Oral administration and distribution of melatonin in human serum, saliva and urine;
- 1986 Feb: A clinical study of the pineal gland activity in oncologic patients;
- 1986 Oct: Human melatonin production decreases with age;
- 1987 Jul: The clinical significance of melatonin serum determination in oncological patients and its correlations with GH and PRL blood levels (Lissoni P, Di Bella L. et al.);
- 1987 Oct: Clinical study of melatonin in untreatable advanced cancer patients;
- 1989 May: Endocrine and immune effects of melatonin therapy in metastatic cancer patients;
- 1990 May: Preliminary studies on melatonin in the treatment of myelodysplastic syndromes following cancer chemotherapy;
- 1990 Dec: Melatonin and human cancer;
- 1990 Feb: A study of the pineal hormone melatonin as a second line therapy in metastatic colorectal cancer resistant to fluorouracil plus folates;
- 1991 Jun: Clinical result with the pineal hormone melatonin in advanced cancer resistant to standard antitumor therapies;
- 1992 ???: Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin;
- 1992 Jul: Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer;
- 1993 Feb: Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: preliminary results;
- 1993 Jun: Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract;
- 1993 Nov-Dec: A study of the mechanisms involved in the immunostimulatory action of the pineal hormone in cancer patients;
- 1993 Dec: Subcutaneous therapy with low-dose interleukin-2 plus the neurohormone melatonin in metastatic gastric cancer patients with low performance status;
- 1994 Jan: A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma;
- 1994 Feb: A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms;
- 1994 May: Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinoma;
- 1994 Jun: Modulation of human lymphoblastoid interferon activity by melatonin in metastatic renal cell carcinoma. A phase II study;
- 1994 Dec: A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer;
- 1995 Apr: Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone;
- 1995 May: A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with untreatable metastatic solid tumour;
- 1995 May-Jun: A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folates;
- 1996 Jan-Feb: Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone;
- 1996 Jul: Is there a role for melatonin in the treatment of neoplastic cachexia?;
- 1996 Jul: Prevention of cytokine-induced hypotension in cancer patients by the pineal hormone melatonin;
- 1996 Nov: Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma;
- 1996 Nov: A phase II study of tamoxifen plus melatonin in metastatic solid tumour patients;
- 1996 Dec: Melatonin and radioprotection from genetic damage: in vivo/in vitro studies with human volunteers;
- 1997 Mar: Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin;
- 1997 Aug: A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state;
- 1997 Sep: Nocturnal urinary 6-sulfatoxymelatonin and proliferating cell nuclear antigen-immunopositive tumor cells show strong positive correlations in patients with gastrointestinal and lung cancer;
- 1998 Jan: A significant correlation between melatonin deficiency and endometrial cancer;
- 1998 Aug: Melatonin: possible mechanisms involved in its 'radioprotective' effect;
- 1998 Aug: Topical melatonin in combination with vitamins E and C protects skin from ultraviolet-induced erythema: a human study in vivo;
- 1999 Feb: Growth Factors: Thrombopoietic Property of the Pineal Hormone Melatonin;
- 1999 Apr: Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin: a phase II study;
- 1999 Oct: Melatonin content in plasma and large intestine of patients with colorectal carcinoma before and after surgery;
- 1999 Nov: Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status;
- 2000 Jul: Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatonin;
- 2000 Nov: Randomized, double-blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment;
- 2001 Apr: Cyclophosphamide plus somatostatin, bromocriptin, retinoids, melatonin and ACTH in the treatment of low-grade non-Hodgkin's lymphomas at advanced stage: results of a phase II trial;
- 2001 Jan: Anti-angiogenic activity of melatonin in advanced cancer patients;
- 2002 Mar: Is there a role for melatonin in supportive care?;
- 2002 May: Patients with advanced primary hepatocellular carcinoma treated by melatonin and transcatheter arterial chemoembolization: a prospective study;
- 2002 Jun: Circadian rhythm of melatonin in patients with colorectal carcinoma;
- 2002 Aug: Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system;
- 2003 Feb-Apr: Reduction of cisplatin-induced anemia by the pineal indole 5-methoxytryptamine in metastatic lung cancer patients;
- 2003 Aug: Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial;
- 2003 Oct: Melatonin slowed the early biochemical progression of hormone-refractory prostate cancer in a patient whose prostate tumor tissue expressed MT1 receptor subtype;
- 2005 Feb: Impact of fish oil and melatonin on cachexia in patients with advanced gastrointestinal cancer: a randomized pilot study;
- 2005 Jun: Melatonin and cortisol serum levels in lung cancer patients at different stages of disease;
- 2005 Nov: Circadian function in patients with advanced non-small-cell lung cancer;
- 2006 Feb: Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in advanced non-small-cell lung cancer patients with low performance status;
- 2006 Nov-Dec: Relapse of high-grade non-Hodgkin's lymphoma after autologous stem cell transplantation: a case successfully treated with cyclophosphamide plus somatostatin, bromocriptine, melatonin, retinoids, and ACTH;
- 2007 Jan-Feb: Low-grade non-Hodgkin lymphoma at advanced stage: a case successfully treated with cyclophosphamide plus somatostatin, bromocriptine, retinoids, and melatonin;
- 2007 Feb: Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in chemotherapy-pretreated patients with advanced lung adenocarcinoma and low performance status;
- 2007 Apr-May: Biochemotherapy with immunomodulating pineal hormones other than melatonin: 5-methoxytryptamine as a new oncostatic pineal agent;
- 2007 Apr-May: Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms;
- 2008 Mar-Apr: Neuroimmunomodulation in medical oncology: application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors;
- 2008 Jun: Urinary 6-sulfatoxymelatonin levels and risk of breast cancer in postmenopausal women;
- 2008 Dec: Complete objective response to biological therapy of plurifocal breast carcinoma;
- 2009 May: A phase II study of anastrozole plus the pineal anticancer hormone melatonin in the metastatic breast cancer women with poor clinical status;
- 2009 Jun: Chronic lymphocytic leukemia: long-lasting remission with combination of cyclophosphamide, somatostatin, bromocriptine, retinoids, melatonin, and ACTH;
- 2009 Jul: Melatonin deficiency and disrupted circadian rhythms in pediatric survivors of craniopharyngioma;
- 2009 Sep: Complete objective response of oesophageal squamocellular carcinoma to biological treatment;
- 2009 Sep: Melatonin and tryptophan circadian profiles in patients with advanced non-small cell lung cancer;
- 2009 Oct: Complete objective response of neuroblastoma to biological treatment;
- 2009 Oct: Endogenous melatonin and oxidatively damaged guanine in DNA;
- 2010 Mar-Apr: Synchronization of cortisol circadian rhythm by the pineal hormone melatonin in untreatable metastatic solid tumor patients and its possible prognostic significance on tumor progression;
- 2010 Apr: Melatonin, a promising role in taxane-related neuropathy;
- 2010 Jul: Enhancement of the efficacy of cancer chemotherapy by the pineal hormone melatonin and its relation with the psychospiritual status of cancer patients;
- 2010 Sep-Oct: Psychoneuroendocrine modulation of regulatory T lymphocyte system: in vivo and in vitro effects of the pineal immunomodulating hormone melatonin;
- 2011 Mar: The use of high-dose melatonin in liver resection is safe: first clinical experience;
- 2011 Sep: The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 122 cases of breast cancer;
- 2012 May: The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 23 tumours of the head and neck;
- 2012 Dec: The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 55 cases of lymphomas;
- 2013 Oct: Therapeutic response of untreatable hepatocellular carcinoma after application of the immune modulators IL-2, BCG and melatonin;
- 2013 Nov: The Di Bella Method (DBM) in the treatment of prostate cancer: a preliminary retrospective study of 16 patients and a review of the literature;
- 2013 Dec: Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonin, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: a preliminary report;
- 2013 Dec: Individual variations in serum melatonin levels through time: implications for epidemiologic studies;
- 2014 Mar: Expression of MT2 receptor in patients with gastric adenocarcinoma and its relationship with clinicopathological features;
- 2014 Jun: A randomized, placebo-controlled trial of melatonin on breast cancer survivors: impact on sleep, mood, and hot flashes;
- 2014 Dec: Melatonin in patients with cancer receiving chemotherapy: a randomized, double-blind, placebo-controlled trial;
- 2015 Feb: Urinary melatonin levels, sleep disruption, and risk of prostate cancer in elderly men;
- 2015 May: Recurrent Glioblastoma Multiforme (grade IV – WHO 2007): a case of complete objective response achieved by means of the concomitant administration of Somatostatin and Octreotide – Retinoids – Vitamin E – Vitamin D3 – Vitamin C – Melatonin – D2 R agonists (Di Bella Method – DBM) associated with Temozolomide;
- 2015 Aug: The effect of melatonin on sleep and quality of life in patients with advanced breast cancer;
- 2016 Jan: Congenital fibrosarcoma in complete remission with Somatostatin, Bromocriptine, Retinoids, Vitamin D3, Vitamin E, Vitamin C, Melatonin, Calcium, Chondroitin sulfate associated with low doses of Cyclophosphamide in a 14-year Follow Up. Case Report;
- 2016 Jan-Feb: Impact of multicomponent, nonpharmacologic interventions on perioperative cortisol and melatonin levels and postoperative delirium in elderly oral cancer patients;
- 2016 Mar-Apr: Melatonin for Prevention of Breast Radiation Dermatitis: A Phase II, Prospective, Double-Blind Randomized Trial;
- 2016 Apr: The Reduction in Circulating Melatonin Level May Contribute to the Pathogenesis of Ovarian Cancer: A Retrospective Study;
- 2016 Apr-Jun: Micronuclei Assessment of The Radioprotective Effects of Melatonin and Vitamin C in Human Lymphocytes;
- 2016 Jul: Pineal calcification is associated with pediatric primary brain tumor;
- 2016 Jul: Urinary melatonin-sulfate/cortisol ratio and the presence of prostate cancer: A case-control study;
- 2016 Aug: Dose dependent sun protective effect of topical melatonin: A randomized, placebo-controlled, double-blind study;
- 2017 Apr: Melatonin Pharmacological Blood Levels Increase Total Antioxidant Capacity in Critically Ill Patients;
- 2017 Jun: Beneficial Effects of Adjuvant Melatonin in Minimizing Oral Mucositis Complications in Head and Neck Cancer Patients Receiving Concurrent Chemoradiation;
- 2017 Aug: Relationships of salivary cortisol and melatonin rhythms to sleep quality, emotion, and fatigue levels in patients with newly diagnosed lung cancer;
- 2017 Dec: Complete objective response, stable for 5 years, with the Di Bella Method, of multiple-metastatic carcinoma of the breast;
- 2018 Mar: Five Year-Survival with High-Dose Melatonin and Other Antitumor Pineal Hormones in Advanced Cancer Patients Eligible for the Only Palliative Therapy;
- 2018 Mar: The Synergism of Somatostatin, Melatonin, Vitamins Prolactin and Estrogen Inhibitors Increased Survival, Objective Response and Performance Status In 297 Cases of Breast Cancer;
- 2018 May: Phase II trial of high-dose melatonin oral gel for the prevention and treatment of oral mucositis in H&N cancer patients undergoing chemoradiation (MUCOMEL);
- 2018 Oct: Evaluation of melatonin and AFMK levels in women with breast cancer;
- 2018 Nov: The protective effects of melatonin on blood cell counts of rectal cancer patients following radio-chemotherapy: a randomized controlled trial;
- 2018 Dec: Disruption of sleep, sleep-wake activity rhythm, and nocturnal melatonin production in breast cancer patients undergoing adjuvant chemotherapy: prospective cohort study;
- 2019 Feb: Phase I dose-finding study for melatonin in pediatric oncology patients with relapsed solid tumors;
- 2019 Apr: Association between nighttime-daytime sleep patterns and chronic diseases in Chinese elderly population: a community-based cross-sectional study;
- 2019 Apr: Different routes and formulations of melatonin in critically ill patients. A pharmacokinetic randomized study;
- 2019 Sep: Serum and Saliva Concentrations of Biochemical Parameters in Men with Prostate Cancer and Benign Prostate Hyperplasia;
- 2019 Nov: The Effects of Melatonin on the Descending Pain Inhibitory System and Neural Plasticity Markers in Breast Cancer Patients Receiving Chemotherapy: Randomized, Double-Blinded, Placebo-Controlled Trial;
- 2019 Dec: Clinical significance of serum melatonin in predicting the severity of oral squamous cell carcinoma;
- 2019 Dec: Effects of half- or whole-night shifts on physiological and cognitive parameters in women;
- 2019 Dec: Efficacy of Melatonin in prevention of radiation-induced oral mucositis: A randomized clinical trial;
- 2020 Mar: A Personalized short-time Immunotherapy with Subcutaneous very low-dose Il-2 plus the Pineal Hormone Melatonin in advanced cancer patients with Persistent Lymphocytopenia;
- 2020 Apr: Clinical impact of melatonin on breast cancer patients undergoing chemotherapy; effects on cognition, sleep and depressive symptoms: A randomized, double-blind, placebo-controlled trial;
- 2020 Sep: Pharmacokinetics and Safety of Intravenous, Intravesical, Rectal, Transdermal, and Vaginal Melatonin in Healthy Female Volunteers: A Cross-Over Study;
- 2020 Oct: Melatonin and Sirtuins in Buccal Epithelium: Potential Biomarkers of Aging and Age-Related Pathologies;
- 2020 Oct: Melatonin increases overall survival of prostate cancer patients with poor prognosis after combined hormone radiation treatment;
- 2020 Oct: Melatonin to prevent delirium in patients with advanced cancer: a double blind, parallel, randomized, controlled, feasibility trial;
- 2020 Dec: The radioprotective effect of melatonin against radiation-induced DNA double-strand breaks in radiology;
- 2020 Dec-2021 Jan: A Randomized, Controlled, Parallel-Group, Trial on the Effects of Melatonin on Fatigue Associated with Breast Cancer and Its Adjuvant Treatments;
- 2021 Feb: A novel signature predicts recurrence risk and therapeutic response in breast cancer patients;
- 2021 Feb: Adjuvant melatonin for the prevention of recurrence and mortality following lung cancer resection (AMPLCaRe): A randomized placebo controlled clinical trial;
- 2021 Feb: Associations between artificial light at night and risk for thyroid cancer: A large US cohort study;
- 2021 Mar: Randomized placebo-controlled phase II trial of high-dose melatonin mucoadhesive oral gel for the prevention and treatment of oral mucositis in patients with head and neck cancer undergoing radiation therapy concurrent with systemic treatment;
- 2021 Apr: Correlation between melatonin concentration and cytokines in cervical mucus in positive samples for the presence of human papillomavirus;
- 2021 Jun: Salivary melatonin in oral squamous cell carcinoma patients;
- 2021 Jun: The Radioprotective Effects of Melatonin and Nanoselenium on DNA Double-Strand Breaks in Peripheral Lymphocytes Caused by I-131;
- 2021 Jun: Treatment of Platelet Deficiency in a Cohort of Patients by a Combination of Melatonin and 5-Methoxytryptamine;
- 2021 Jul: Melatonin inhibits lung cancer development by reversing the Warburg effect via stimulating the SIRT3/PDH axis;
- 2021 Aug: Use of Melatonin Is Associated With Lower Risk of Colorectal Cancer in Older Adults;
- 2021 Sep: Identification of Key Regions Mediating Human Melatonin Type 1 Receptor Functional Selectivity Revealed by Natural Variants;
- 2021 Sep: Melatonin enhances radiofrequency-induced NK antitumor immunity, causing cancer metabolism reprogramming and inhibition of multiple pulmonary tumor development;
- 2021 Oct: Parameters of Oxidative Stress, Vitamin D, Osteopontin, and Melatonin in Patients with Lip, Oral Cavity, and Pharyngeal Cancer;
- 2021 Nov: A retrospective observational study on cases of anaplastic brain tumors treated with the Di Bella Method: A rationale and effectiveness (from Di Bella's Foundation);
- 2021 Dec: Decreased Circulating Melatonin with Loss of Age-Related Biphasic Change in Patients with Oral Squamous Cell Carcinoma;
- 2022 Jan: The efficacy of melatonin against radiotoxicity of iodine-131 and its response to treatment in hyperthyroid patients: a randomized controlled trial;
- 2022 Jun: A Retrospective Observational Study on Cases of Sarcoma Treated with the Di Bella Method: Rationale and Effectiveness (from Di Bella's Foundation);
- 2022 Sep: A retrospective observational study on cases of osteosarcomas treated with a multitherapy: The rationale and effectiveness (from Di Bella's Foundation);
- 2022 Nov: Quality-of-life outcomes following topical melatonin application against acute radiation dermatitis in patients with early breast cancer: A double-blind, randomized, placebo-controlled trial.